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Mitochondrial reactive oxygen species (ROS) are recognized for their role in several health 
related problems when produced at excessively high concentrations. Due to their potent 
antioxidant activity and potential mitochondriotropic behavior, the anthocyanidins may have 
potential to lower mitochondrial ROS levels. Nevertheless, the effect of anthocyanidins remains 
overlooked due to their presumed low stability and bioavailability. In addition, this instability has 
lead to a general belief that the phenolic degradation products, protocatechuic acid (PCA) and 
phloroglucinaldehye (PGA), exert the bioactivity rather than the parent compound.  
In this work, doxorubicin-induced cytotoxicity in differentiated H9c2 cardiomyocytes was 
initially established as a model in which the mitochondrial antioxidant activity of the selected 
flavonoids would be examined. First, we delineated the mechanisms by which doxorubicin 
affected H9c2 cell survival and mitochondrial function. The results showed that early effects of 
doxorubicin on mitochondrial superoxide generation led to a delayed effect on cell survival. Using 
this model, we then revealed the protective ability of cyanidin against doxorubicin-induced 
cytological damage, showing protection to mitochondria. While cyanidin co-incubation with 
doxorubicin did not show protection when cell survival was assessed after 24 h, it gave delayed 
protection after a further 24 h drug-free period. Using the delayed protection model, we also 
showed that cyanidin had greater bioactivity over other flavonoids tested (quercetin, catechin and 
cyanidin-3-glucoside (C3G)). The protection by cyanidin also exceeded that of its degradation 
products (PCA and PGA), suggesting that the parent compound has additional bioactivity. The 
cytoprotective ability of the flavonoids was related to their ability to lower mitochondrial 
superoxide at early time points, with cyanidin being the most effective. Experiments on 
doxorubicin cytotoxicity to HepG2 (liver cancer) and K562 (erythroleukemia) cells showed no 
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protective effect with cyanidin. These results suggest cyanidin protects cardiomyocytes but does 
not interfere with the cytotoxic activity of doxorubicin in the cancer cell lines.  
Investigations on the degradation of cyanidin in physiological media, UV-vis, HPLC and 
MS analytical techniques provided evidence that cyanidin does not degrade immediately to PCA 
and PGA. Instead, intermediate compounds (hemiketal and chalcone) survived for sufficient 
periods to exert putative bioactivity. Studies on the influence of different medium on the 
degradation of cyanidin showed that stability in human serum was significantly higher (t½ 43.2 
min at room temperature, 22 ± 1°C) compared to phosphate buffered saline and Dulbecco’s 
Modified Eagle’s Medium with and without 10% fetal bovine serum (t½ 10.2-32.6 min).     
In conclusion, using differentiated H9c2 cells, our results show an ability of cyanidin to 
survive long enough in cell culture media, and presumably intracellularly, to exert cytoprotection 
against doxorubicin which exceeded that of other flavonoids (quercetin, catechin, C3G) and its 
degradation products (PCA and PGA). The results present cyanidin as a possible antioxidant 
choice to use in clinical practice to protect the heart from the mitochondrial toxicity of doxorubicin 
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW  
 
1.1. INTRODUCTION 
Mitochondrial reactive oxygen species (ROS) have been implicated in aging, cancer and 
several mitochondrial diseases when found in excessively high concentrations. Lowering the 
concentrations of mitochondrial ROS, may then mitigate their health related problems. Flavonoids, 
including anthocyanidins, are known for their antioxidant behaviour and ability to decrease 
concentrations of ROS (Kahkonen and Heinonen, 2003). The enhanced mitochondriotropic 
characteristic of anthocyanidins over other flavonoids (Peng, 2012) potentially enables their 
enhanced protection against mitochondrial oxidative stress. Their favourable more positive charge 
in physiological conditions compared to other flavonoids (such as catechin and quercetin) and 
sufficient lipophilicity (compared to cyanidin-3-glucoside (C3G)) may be two crucial 
characteristics that enables their attraction towards the mitochondrial matrix side of the inner 
membrane. However, despite these favourable structural features, anthocyanidins are presumed to 
suffer from low stability and oral bioavailability. Given these characteristics, the health benefits 
of anthocyanins/anthocyanidins are generally believed to be mediated by their phenolic 
degradation products; protocatechuic acid (PCA) and phloroglucinaldehyde (PGA) (Kay et al, 
2009). However, observations from the literature (Peng, 2012; Rodriguez-Mateos et al, 2014; 
Stevens and Maier, 2016) have challenged this claim and suggest that cyanidin itself or other 
compounds in the cyanidin degradation pathway act as potent bioactive agents.  
The novelty of this work is to provide evidence that the mitochondriotropic property of 
cyanidin may provide better cytoprotective activity than other potent flavonoids (quercetin, 
catechin, C3G) and its degradation products (PCA, PGA) against a mitochondrial oxidative stress 
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inducer, such as doxorubicin. Also, despite the favourable protective activities of antioxidants, 
their ability to lower ROS may impede the cytotoxicity of cancer chemotherapies reducing the 
therapeutic benefit of chemotherapeutics against cancer cells. We therefore investigated the effect 





1.2. LITERATURE REVIEW 
1.2.1. Reactive oxygen species   
 ROS are strong oxidants formed intracellularly in mitochondria (Kirkinezos et al, 2001), 
endoplasmic reticulum (Zeeshan et al, 2016), and peroxisomes (Sandalio et al, 2013). They are 
also associated with plasma membrane NADPH oxidase activity (Panday et al, 2015).  ROS 
include many molecules such as peroxides, superoxide, hydroxyl radical and singlet oxygen. At 
physiological levels, ROS have a crucial role in many physiological processes such as embryo 
development (Dennery et al, 2007), muscle exercise (Barbieri and Sestili, 2012; Steinbacher and 
Eckl, 2015) and macrophage function (Hsu and Wen, 2002). At the cellular level, ROS play a 
significant role in apoptosis, cell proliferation  (Circu and Aw, 2010; Schieber and Chandel, 2014) 
and cell signaling (Thannickal and Fanburg, 2000). Despite these important roles, excessive ROS 
production leading to oxidative stress is implicated in a number of pathological conditions 
including cancer, aging, stroke, heart failure, and neurodegenerative diseases (Alvarez, et al, 2008; 
Armstrong, 2010; Belin et al, 2007; Davidson, 2010; de Moura et al, 2010; Fang et al, 2002; 
Gaweda-Walerych et al, 2013; Harman, 1972; Ladiges et al, 2010; Popa-Wagner et al, 2013; Popa-
Freidovich, 1999; Schieber and Chandel, 2014; Witte et al, 2010;  Zuo et al, 2015).  
ROS cause cytotoxicity by reacting with important cellular macromolecules. Reactions 
with DNA, for example, can cause extensive damage to its structure leading to cell death (Gabbita 
et al, 1998; Lovell et al, 2007). In addition, ROS can attack the double bonds in unsaturated lipids 
causing the generation of highly reactive lipid peroxy radicals, which can further attack other 
unsaturated fatty acids in a chain reaction leading to extensive cellular damage (Berlett and 
Stadtman, 1997; Dalle-Donne et al, 2006). Moreover, these compounds can result in protein 
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modifications that can disrupt many functions and initiate apoptosis (Gella and Durary, 2009; 
Keller et al, 1997; Mattson et al, 2003).  
To overcome oxidative stress, a condition caused by excessive production of ROS, many 
endogenous enzymes and exogenous antioxidants may react with ROS to suppress their reactivity. 
These agents have a common ability of scavenging ROS and minimizing their harmful effects 
(Birben et al, 2012; Grabacka et al, 2014). The widely variable exogenous antioxidants are 
divided into many classes and subclasses based on their chemical structure and characteristics.  
1.2.2. Oxidative damage and mitochondrial ROS-related diseases  
Mitochondrial oxidative stress and mitochondrial damage have been associated with the 
normal aging process and several different clinical implications including cancer, and certain 
neurological, muscular and cardiovascular diseases (Ballinger, 2005; Harman, 1956; Liou and 
Storz, 2010; Miquel et al, 1980; Terrill et al, 2013). For example, myocardial infarction, heart 
failure, and ischemia-reperfusion are conditions that involve elevated mitochondrial ROS (Gao et 
al, 2008; Tsutsui et al, 2006). Therefore, inhibition of mitochondrial ROS has been a reasonable 
approach to reduce the complications of these illnesses (Gao et al, 2008; Dhalla et al, 2000; Handy 
and Loscalzo, 2012; Madamanchi and Runge, 2007; Matsushima et al, 2006; Zhang and 
Gutterman, 2007).  
1.2.3.  ROS production in physiological conditions: involvement of the electron transport 
chain (ETC) and the fate of ROS once formed 
Approximately 1-3% of mitochondrial oxygen consumption results in the production of 
ROS (Kirkinezos et al, 2001) making this organelle a major site of cellular ROS generation (Ott 
et al, 2007). Therefore, mechanisms of mitochondrial ROS production in physiological conditions 
have been widely investigated. The involvement of the electron transport chain (ETC) in the 
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production of ROS is well characterised. The widely accepted explanation to the production of 
ROS is the “leakage” of the electrons from the ETC, particularly from complexes I and III, and 
reduction of oxygen to form the superoxide free radical and other ROS (Figure 1.1). (Cadenas 
and Davies, 2000; Murphy, 2009; Turrens, 2003)  
 
Figure 1.1: Mitochondrial complexes and reactive oxygen species (ROS) production. The 
electron transport chain (ETC) involves oxidation of electron carriers, NADH and FADH2, and 
reduction of ubiquinone in mitochondrial complexes I and II. The energy released during the 
transport of the electrons is used by the complexes to pump protons from the mitochondrial matrix 
to the inter membrane space. The proton gradient formed across the membrane is utilized by ATP 
synthase (complex V) to generate ATP. The electrons are used to reduce oxygen to water at 
complex IV. ROS is released by the leakage of electrons from mainly complexes I and III to reduce 
oxygen and form a free-radical superoxide and other ROS. (Cadenas and Davies, 2000; Osellame 
et al, 2012; Turrens, 2003). 
 
Several mechanisms exist to prevent the accumulation of ROS in cells. Once superoxide 
(O2
•−) molecules are formed, their half-life is short and several fates await them. They can form 
other oxygen derived reactive species such as peroxyl radical (RO2•), hypochlorous acid (HOCl), 
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and alkoxyl radical (RO•). Alternatively, the negatively charged superoxide reacts rapidly with 
nitric oxide (NO•) to form the potent oxidant peroxynitrite (ONOO−) and other reactive nitrogen 
species (RNS). Superoxide is also able to interact with some mitochondrial iron-sulfur containing 
proteins causing further damage to the mitochondria (Powers and Jackson, 2008). Cellular 
superoxide can also be rapidly dismutated to hydrogen peroxide (H2O2) spontaneously or via 
superoxide dismutase 1 (SOD1), 2 (SOD2) and 3 (SOD3) (Cadenas and Davies, 2000; Fridovich, 
1986).  H2O2 can penetrate membranes and oxidize thiol groups on cellular enzymes (Vranova et 
al, 2002). H2O2 can also react with Fe
2 + to produce the highly reactive hydroxyl radical (OH•) by 
the Fenton reaction (Halliwell and Gutteridge, 1990). The OH• is a very reactive molecule with 
strong oxidizing potential enabling it to interact with and damage any macromolecule in its 
proximity. Collectively, many mechanisms exist to prevent ROS from increasing to oxidative 
stress levels. Although highly efficient, these mechanisms may be overwhelmed by the many 
intrinsic and extrinsic factors that increase ROS levels. Examples of these extrinsic factors include 
ultraviolet (UV) irradiation, redox-cycling of quinones, medications, toxicants, metals and aging 
(Beal, 2005; Carvour et al, 2008; Kitazawa et al, 2002; 2001; Sheu et al, 2006). 
1.2.4. ROS production as a side effect of medications and food  
 Medications and food consumption are associated with increases in ROS production. For 
example, high intakes of carbohydrates and fats are known to increase ROS production in muscles 
(Gregersen et al, 2012), liver and vascular system (Lozano et al, 2016). Food additives such as 
aspartame (Iyyaswamy and Rathinasamy, 2012) and food-borne toxins such as dioxins (Reichard 
et al, 2006) and nitrosamines (Ahotupa et al, 1987) are also reported to increase oxidative stress 
in different organs.  
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  Many medications also contribute to elevations in ROS production. Common medications 
like acetaminophen (Jiang et al, 2015) and other non-steroidal anti-inflammatory drugs (Ghosh et 
al, 2015; Tomita et al, 2014) can increase hepatic and intestinal levels of ROS, respectively. Some 
cancer chemotherapeutic drugs increase ROS in normal cells causing dose limiting toxicities. 
Organ specific toxicities associated with chemotherapeutic agents such as 5-fluorouracil (5-FU) 
and cisplatin, is due to increases in ROS in specific cell types (Focaccetti et al, 2015, Lamberti et 
al, 2012; Minotti et al, 2004; Qian et al, 2018; Zhang et al, 2017; Zhang et al, 2009a). In particular, 
the chemotherapeutic agent doxorubicin has been shown to cause ROS-related cardiotoxicity. 
1.2.5. The mechanism of toxicity of doxorubicin 
Doxorubicin is a chemotherapeutic agent that is widely used for different cancer types 
(Wells et al, 2009). It exerts its anti-cancer biological activity by intercalation into DNA and 
inhibiting topoisomerase-II (Top2) (Gewirtz, 1999; Tewey et al, 1984; Thorn et al, 2011). 
Doxorubicin binds both DNA and Top2 (particularly Top2α) to form a Top2-doxorubicin-DNA 
cleavage complex to cause cell death. Despite its wide implementation in various cancer therapy 
regimens, its dosage is limited by cardiotoxicity and other organ toxicity (Chatterjee et al, 2010; 
Tangpong et al, 2011). Although other mechanisms have been proposed (Minotti et al, 2004; 
Zhang et al, 2012; Zhang et al, 2009b), it is generally believed that the main cause for 
cardiotoxicity is the over production of ROS in heart mitochondria (Berthiaume and Wallace, 
2007; Doroshow, 1983; Singal and Iliskovic, 1998).  
 Many direct and indirect mechanisms have been investigated to explain the elevation in 
ROS levels following treatment with doxorubicin (Kim et al, 2006; Tsang et al, 2003; Wei et al, 
2015). The production of ROS in heart cells, which are rich in mitochondria, is thought to be 
mediated by redox-cycling activity caused by the interaction of doxorubicin with complex I 
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(Davies and Doroshow, 1986; Tokarska-Schattner et al, 2006). The increase in mitochondrial 
superoxide levels and ROS was observed in many reports in different cell lines including 
cardiomyocytes (Branco et al, 2012, Mukhopadhyay et al, 2007; Mukhopadhyay et al, 2009; 
Octavia et al, 2012; Tsang et al, 2003). Also, ROS scavengers have been partially successful in 
reducing the cardiomyocyte toxicity of doxorubicin (Chacko et al, 2015), emphasizing the role of 
ROS in doxorubicin toxicity to cardiomyocytes. 
 In heart cells, doxorubicin is proposed to react with complex I resulting in the reduction of 
doxorubicin by the flavoproteins to form a radical semiquinone form (Figure 1.2). The 
semiquinone is oxidized by molecular oxygen to the quinone form and the superoxide radical 
which acts as a precursor to other ROS.   
 
Figure 1.2: Cellular metabolism of doxorubicin and the formation of free radicals. Initially, 
doxorubicin is reduced by flavoproteins (such as mitochondrial complex I in heart cells), to form 
a radical semiquinone form. The fate of the semiquinone depends on the presence of oxygen, which 
is often high in cardiomyocytes. The semiquinone is oxidized in the presence of oxygen back to 
the quinone form. A superoxide radical is formed from the reaction which together with other ROS 
can react with proteins, DNA and lipids contributing to cellular toxicity. (Adapted from Davies 
and Doroshow, 1986; Tokarska-schattner et al, 2006). 
 
The increase in mitochondrial ROS is presumed to be the main cause of toxicity in heart 
cells (Berthiaume and Wallace, 2007; Doroshow and Davies, 1986; Octavia et al, 2012; Singal 
and Iliskovic, 1998). Cardiomyocytes are rich in mitochondria (Stanley, 2004) and depend 
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principally on mitochondrial oxidative phosphorylation and complex I. The reaction of 
doxorubicin with this complex, then would cause redox-cycling activity and possibly a rapid 
increase in ROS upon exposure to doxorubicin. However, except in one (Mukhopadhyay et al, 
2007), studies report increases after longer periods of incubations ranging from 12-48 hours (h) 
using concentrations between 1 and 5 µM (Bernuzzi et al, 2009; Cheung et al, 2015; Hosseinzadah 
et al, 2011; Tan et al, 2010). Such prolonged exposures with doxorubicin suggests apoptosis as a 
mechanism of ROS increase (Akopova et al, 2012, Chen et al, 2003) rather than a direct redox-
cycling activity in the heart.  
The usage of H9c2 cells as an in vitro model to evaluate the cardiotoxicity of many 
compounds, including doxorubicin, is widely accepted (Enayetallah et al, 2013). Much of the 
research on cytotoxicity, ROS and mitochondrial superoxide generation, as well as effects on 
mitochondrial membrane potential (MMP) with doxorubicin has involved undifferentiated H9c2 
cells (Choi et al, 2007; Deus et al, 2015; Mukhopadhyay et al, 2007; 2009). The mechanism of 
doxorubicin cytotoxicity may be different between actively dividing cells and differentiated 
cardiomyocytes. In actively dividing cancer cells the mechanism is primarily by DNA intercalation 
and interference with DNA replication (Thorn et al, 2011), while the mechanism for cardiotoxicity 
is thought to be mitochondrial redox-cycling and ROS production (Berthiaume and Wallace, 2007; 
Doroshow and Davies, 1986; Octavia et al, 2012; Singal and Iliskovic, 1998). The literature 
indicates that differentiated H9c2 have phenotypes more similar to mature cardiomyocytes in vivo 
and thus would more accurately represent the mechanism of doxorubicin-induced cardiotoxicity 





1.2.6. Scavenging of ROS by antioxidant agents 
 The human diet contains a wide array of antioxidant chemicals that have attracted attention 
and efforts to identify, characterize and evaluate their toxicity and efficacy (Devasagayam et al, 
2004; Grabacka et al, 2014; Huh et al, 2004; Miki et al, 2012; Sies and Stahl, 1995). These 
antioxidants have the ability to scavenge radicals and may assist in treating or preventing many 
diseases caused by oxidative stress (Hajhashemi et al, 2010; Pham-Huy et al, 2008).  
Several epidemiological studies showed that ingestion of antioxidant compounds or diets 
containing antioxidants has beneficial anti-inflammatory, anti-atherosclerotic, antitumor, 
antimutagenic, anticarcinogenic, antibacterial and antiviral activities (Hertog et al, 1995; Mitscher 
et al, 1996; Sala et al, 2002; Sun et al, 2002; Yang et al, 2001). Whether these observations can 
be shown in interventional controlled studies is still controversial (Baynes, 1999; 1991; Chang et 
al, 1993; Halliwell and Gutteridge, 1990; McLennan et al, 1991; Young et al, 1995). Despite the 
many challenges, the low toxicity profile of anthocyanidins, their numerous clinical applications, 
low cost, and broad availability could encourage further investigation into their possible clinical 
applications.  
 Interventional studies with dietary antioxidants have shown limited benefit due to a number 
of factors that are often poorly acknowledged in the design of these studies. Factors that can 
contribute to the limited activity include: 1) Low oral bioavalability associated with a majority of 
flavonoid antioxidants due to low intestinal absorption and high first pass metabolism 
(Thilakarathna and  Rupasinghe, 2013); 2) Instability of some antioxidants, such as certain 
flavonoids, in the gastrointestinal tract resulting in tissues levels too low to exert an activity 
(Braune et al, 2001; Fleschhut et al, 2006; Ramesova et al, 2012); 3) Limited distribution and 
accumulation of antioxidants into mitochondria to address excessive mitochondrial ROS (Fiorani 
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et al, 2010; Peng, 2012); 4) The low potency of many natural antioxidants and/or the extremely 
rapid and high damaging effects of oxidants may hinder their bioactivity (Cadenas and Davies, 
2000; Fridovich, 1986; Halliwell and Gutteridge, 1990; Milani et al, 2011; Powers and Jackson, 
2008),  requiring the ingestion of high quantities of antioxidant-rich food to reach a therapeutic 
effect (Hagiwara et al, 2001; Pojer et al, 2013); and 5) A limited knowledge of the pathophysiology 
of disease (Diaz-Hung and González Fraguela, 2014) and of  antioxidant pharmacology (Covey et 
al, 2006) has underestimated their efficacy. These observations stress the importance of evaluating 
available antioxidants to comprehensively understand their behaviour and to reveal lead 
compounds for the synthesis of new agents with enhanced bioactivities. For example, the ability 
to accumulate in the mitochondria is evidently a crucial feature to improve the bioactivity of 
antioxidants in situations involving mitochondrial oxidative stress. Therefore, emphasis has been 
directed towards characterising new antioxidants with ability to accumulate into mitochondria.   
1.2.7. Non mitochondria-targeted antioxidants 
Antioxidants are widely used for their possible health benefits (Injac and Strukelj, 2008; 
Devasagayam et al, 2004).  Antioxidant vitamins, particularly vitamin E and C, have received 
considerable attention due to their high bioavailability and potential to scavenge ROS (Conti et 
al, 2016; Fahn et al, 1992; Lan and Jiang, 1997; May, 1999; Odunze et al, 1990; Roghani and 
Behzadi, 2001; Sano et al, 1997; Wang and Quinn, 2000).  
The polyphenol, resveratrol has shown moderate potency in lowering ROS levels in in 
vitro studies. Further, resveratrol restores the normal level of endogenous antioxidants by 
inducing expression of glutathione and antioxidant enzymes via activation of the redox sensitive 
transcription factor nuclear erythroid-related factor 2 (Nrf2) (Kode et al, 2008). For example, 
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resveratrol was able to increase the expression of MnSOD in mouse brains (Robb et al, 2008) 
leading to decreased lipid peroxidation (Baur et al, 2006; Khanduja et al, 2004).  
Many other antioxidants have been investigated for their bioactivity. For example, dietary 
co-enzyme Q10 (CoQ10, or ubiquinone) also successfully demonstrated antioxidant and 
neuroprotective activities in mice (Wadsworth et al, 2008). Endogenous CoQ10 is localized in 
the inner mitochondrial membrane where it acts as an electron carrier from complex I and 
complex II in the ETC and transfers electrons to complex III. Acetyl-L-carnitine (ALCAR) (Ames 
and Liu, 2004) and R-alpha lipoic acid (RLA) (Maczurek et al, 2008) were also investigated for 
their activity as antioxidants. RLA is reduced to dihydrolipoic acid which has antioxidant activity. 
The combination of both RLA and ALCAR decreased ROS mediated damage, reduced 
mitochondrial damage and improved cognitive and motor functions in rats (Aliev et al, 2009; 
Haenen and Bast, 1991; Long et al, 2009).   
In general, in vitro studies indicate high concentrations of these chemicals provide 
significant protection from elevated ROS. Nevertheless, disappointing results were found in many 
in vivo studies (Etminan et al, 2005; Padayatty et al, 2003; Parkinson Study Group, 1993; Scheider 
et al, 1997; Seidl and Potashkin, 2011; Weber et al, 2006; Zhang et al, 2002).  
1.2.8. Mitochondria-targeted antioxidant therapy 
Since mitochondria are a major site for ROS production (Ott et al, 2007), targeting this 
organelle is anticipated to increase the effectiveness of antioxidants in conditions of mitochondrial 
oxidative stress (Oyewole and Birch-Machin, 2015; Smith and Murphy, 2011). However, limited 
reports have compared the bioactivity for mitochondria-targeted to non-targeted antioxidants in 
ROS-linked illnesses. One study (Jauslin et al, 2003) showed the enhanced activity of 
mitochondria-targeted antioxidants over the untargeted antioxidants in protecting against oxidative 
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stress in Friedreich Ataxia fibroblasts. However, evidence for the improved bioactivity of 
mitochondrial-targeted antioxidants is very limited. Various strategies have been evaluated to 
enhance the mitochondrial accumulation of potential antioxidants. One approach that is generally 
accepted is conjugating an antioxidant to a positively charged lipophilic molecule which 
accumulates in the mitochondria. The positive charge is attracted by the mitochondrial matrix 
negative charge caused by the large mitochondrial membrane potential (ΔΨm) of 150-180 mV. 
Many antioxidants have been conjugated to a triphenylphosphonium (TPP) cation (Liberman et 
al, 1969; Murphy and Smith, 2007; Ross et al, 2005), which has the suitable chemical features 
(positive charge and lipophilicity) to enable it to accumulate in mitochondria (100- to 500-fold 
higher concentration than the cytoplasm) (Smith et al 1999, 2003). Based on this approach, several 
mitochondria-targeted antioxidants with good bioavailability were synthesized including MitoQ, 
MitoVitE, and MitoTEMPOL (Murphy and Smith, 2007; Ross et al, 2005). Treatments with these 
compounds resulted in significant protection from neurodegenerative and cardiovascular diseases 
in different mouse models (Fetisova et al, 2010; Hobbs et al, 2008; Owada et al, 2017; Sheu et al, 
2006; Smith and Murphy, 2010; Zang et al, 2012). 
1.2.8.1. MitoVitE  
MitoVitE (mitotocopherol) is TPP+ conjugated to an α-tocopherol moiety by a two-carbon 
chain in place of the phytyl side chain. It was found to be effective in protection against oxidative 
stress-induced aortic endothelial cell apoptosis (Davidson, 2010; Li, 2013). It accumulates in the 
inner membrane of the mitochondria of different tissues and protects the cells from lipid 
peroxidation and oxidative stress (Smith et al, 1999; Smith et al, 2003; Smith and Murphy, 2011). 
In an in vitro study on fibroblasts from Friedrich Ataxia patients, MitoVitE protected the cells 
from oxidative stress-induced cell death (Jauslin et al, 2003). Animal models showed protection 
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by MitoVitE against cardiac damage in septic pneumonia animal models (Zang et al, 2012). 
Despite these favourable effects, MitoVitE showed neurotoxicity at high doses in some animal 
models explaining the possible reason for the limited number of human clinical trials (Covey et 
al, 2006). 
1.2.8.2. MitoTEMPOL  
MitoTEMPOL consists of TPP+ conjugated with a stable piperidine nitroxide radical 
TEMPOL (4-hydroxy-2,2,6,6,tetramethyl-piperidine-1-oxyl) designed to target the mitochondria. 
In many cellular models, MitoTEMPOL was able to protect cells from oxidative stress (Lim et 
al, 2011; Kizhakekuttu et al, 2012). In addition, a few in vivo evaluations have shown protective 
effects against cardiovascular diseases (Cho et al, 2013; Pung et al, 2012).  
1.2.8.3. Other “Mito” compounds  
Many “mito” compounds have been developed. MitoApocynin (conjugated with the 
NADPH oxidase inhibitor and antioxidant, apocynin), MitoPBN (conjugated with a carbon-
centered radical reactor, phenoxy-butyl-nitrone) (Barclay and Vinqvist, 2000) and 
MitoPeroxidase (conjugated with the glutathione peroxidase-like actor, ebselen) (Mugesh et al, 
2001) are compounds that conjugate TPP+ with different antioxidants. These conjugates 
accumulate in mitochondria and exert an activity in some in vivo animal models (Ghosh et al, 
2016) but these molecules require evaluation of their effectiveness in human studies targeting 
different diseases (Jin et al, 2014).  Another conjugate, SkQ1, a plastoquinone covalently bound 
to TPP+ that acts as a potent antioxidant in isolated mitochondria (Antonenko et al, 2008) and 
cell cultures (Skulachev et al, 2011) also shows promise in reducing oxidative stress in different 
animal models of disease (Agapova et al, 2008; Anisimov et al, 2008; Bakeeva et al, 2008; 
Neroev et al, 2008).   
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1.2.8.4. Szeto-Schiller (SS) tetrapeptides and alternative targeting approaches 
 Many side effects of TPP+ have been reported (Murphy, 2008; Trnka et al, 2015). For this 
reason, different strategies that target the mitochondria have been adopted. Dependent on the 
mitochondrial potential, the Szeto-Schiller (SS) tetrapeptides are believed to target the 
mitochondria due to their aromatic-cationic motif (Zhao et al, 2004; 2003). The most currently 
studied compounds of this group are SS-20 and SS-31. They are selectively localized to the inner 
mitochondrial membrane (Zhao et al, 2005) and have a dimethyltyrosine (Dmt) residue, which 
acts as a free radical scavenger (Szeto et al, 2008). Promising results have been shown for the 
peptide’s antioxidant potency in neuronal in vitro studies as well as one animal study (Reddy et 
al, 2006; Yang et al, 2009; Zhao et al, 2005). However, whether its antioxidant activity or other 
unknown mechanism is responsible for the neuroprotection is undetermined (Yang et al, 2009).   
1.2.9 Flavonoids 
 Positive outcomes in treating/preventing many mitochondrial ROS related diseases in vitro 
and in vivo provide potential evidence for the benefit of targeting the mitochondria. However, 
disadvantages exist with the available mitochondria targeting moieties, such as TPP+, as these 
compounds can lead to toxicity. Moreover, some of the available mitochondria-targeted 
antioxidants have apparent low potency. This can be inferred from the high concentrations required 
in in vitro studies. Therefore, an urgent need for the development of other mitochondrial targeted 
antioxidants with good potency, low cost and low toxicity is required. The flavonoids, particularly 
the anthocyanin subclass, may serve as a natural alternative to target the mitochondria. 
Flavonoids are found in many fruits, vegetables and other foods consumed regularly by 
humans. Due to their strong in vitro antioxidant potency, these compounds have been tested for 
their anti-carcinogenic, anti-inflammatory, anti-mutagenic and cellular protection activity 
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(Darvesh et al, 2010; Havsteen, 2002; Hu 2007; Kumar and Pendey, 2013; Middleton et al 2000; 
Xiao et al, 2011; Yao et al, 2004). Epidemiological evidence suggests flavonoid rich diets lower 
risks of cardiovascular disease, type 2 diabetes, neurological disease, and cancer (Bazzano et al, 
2003; Dauchet and Dallongeville, 2008; Eichholzer et al, 2001; Garcia-Closas et al, 1999; Hertog 
et al, 1997; 1993; Mink et al, 2007; Zunino, 2009).  
  The cytoprotective effect of some flavonoids against doxorubicin has been tested in vitro 
or in vivo (eg. Chen et al, 2013; Choi et al, 2007; Chularojmontri et al, 2013; Dong et al, 2014; 
Han et al, 2012; Kaiserova et al, 2007; Mandziuk et al., 2015a; 2015b; Mojzisova et al, 2009; van 
Acker et al, 2001; Wang et al, 2013). However, some of these studies (eg. Choi et al, 2010) used 
crude extracts rather than pure compounds. In addition, only a few studies (eg. Kaiserova et al, 
2007; van Acker et al, 2001) conducted a comparative analysis between different classes of 
flavonoids. Such studies are crucial in understanding the structure-activity relationship in 
decreasing mitochondrial ROS, or designing new compounds, with a better bioactivity profile.  
1.2.9.1. Structure/Subclasses  
 The basic structure of flavonoids contains two benzene rings and one heterocyclic pyran 
or pyrone ring (Figure 1.3). The roughly 6400 natural flavonoid compounds found in various 
plants share the same structure with different functional groups attached to the benzene and the 
heterocyclic rings. Depending on the hydroxylation pattern, conjugation between the aromatic 
rings, methoxy groups and glucosidic moieties, the compounds are subdivided into six major 
subclasses. These subclasses include flavones, flavonols, flavanones, flavanols (catechins), 
anthocyanidins and isoflavones (Beecher, 2003). Two related subclasses, which include chalcones 
and dihydroflavonols, are also found in nature (Heim et al, 2002). Flavonoids are primarily found 
in nature in their glucosylated form. The carbohydrate moieties are usually attached at locations 
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3 and 7. These carbohydrates include D-glucose, L-rhamnose, D-glucorhamnose, D-galactose, 
lignin, and D-arabinose (Heim et al, 2002).      
















Figure 1.3: Basic flavonoid structure. The presence and location of the different functional 
groups forms the wide variety of flavonoid compounds (Adapted from Heim et al, 2002). 
  
1.2.9.2. Flavonoid antioxidant properties   
 Dietary plant compounds, especially flavonoids and other polyphenols, have been widely 
investigated for their antioxidant activity. Despite their low bioavailability, the potent antioxidant 
activity of flavonoids has been supported by evidence for their protection against oxidative stress 
related diseases (Darvesh et al, 2010; Havsteen, 2002). The protective effect observed by a wide 
range of studies encouraged further research into the health benefits of these chemicals.  
Flavonoids are believed to protect against oxidative damage by scavenging free radicals 
and chelating transition-metals involved in free radical production (Aruoma, 2003). Flavonoids 
can donate a hydrogen atom from an aromatic hydroxy group to a free radical. The process forms 
a stable phenolic delocalized radical and reduces the reactive oxygen radical (Rice-Evans et al, 
1996).  
Flavonoid (OH) + R•         Flavonoid(O•) + RH 
Free radicals such as hydroxyl, lipid alkoxyl, peroxyl and superoxide and other ROS such 
as hypochlorous acid can all be scavenged by flavonoids (Heim et al, 2002; Rice-Evans et al, 
1996). Quercetin and rutin also can lower ROS by chelating transition metal ions thus decreasing 
their ability to promote reactive species formation (Afanasev et al, 1989). Also, flavonoids such 
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as quercetin, myricetin and fisetin can induce the endogenous antioxidant enzymes such as 
glutathione-S-transferase, thus causing a reduction in ROS (Elliott et al, 1992; Filipe et al, 2002).   
  In vivo and in vitro studies suggest that the antioxidant activity of flavonoids may protect 
against oxidative stress related diseases (Middleton et al, 2000; Rein et al, 2000). In cardiovascular 
disease, the ability of flavonoids to inhibit the production of lipid hydroperoxides mitigates the 
development of coronary artery disease (de Whalley et al, 1990; Middleton et al, 2000; Nijveldt 
et al, 2001). The antioxidant activity of flavonoids also has benefit in liver (Peres et al, 2000; 
Pisonero-Vaquero et al, 2015), neurological (Vauzour et al, 2008) and muscular (Malaguti et al, 
2013) disorders. In addition to their antioxidant activity, flavonoids show antimutagenic, 
anticarcinogenic, anti-allergic, and anti-inflammatory effects (Darvesh et al, 2010; Havsteen, 
2002; Middleton et al, 2000; Middleton and Kandaswami, 1992; Nijveldt et al, 2001; Obrenovich 
et al, 2010). These properties may be exploited to mitigate the negative effects of other 
chemotherapeutic agents, as exemplified  by the cardioprotective effects of anthocyanidins (such 
as cyanidin) and flavonols (such as quercetin) against doxorubicin cardiotoxicity in one in vitro 
and in vivo studies (Choi et al, 2007; Dong, 2014; Kaiserova et al, 2007; Sadzuka et al, 1997). 
These results provide important evidence that flavonoids can be utilized to promote human health. 
However, these studies fail to compare the activities of anthocyanidins with other flavonoids 
subclasses. Such comparison is highly crucial in understanding the significance of certain 
structural features present in anthocyanidin. In addition, these studies evaluate the protective 
activity of anthcyanidins when cells are incubated with doxorubicin for extended periods (24-48 
h). The extended incubations with doxorubicin apoptosis mediated increase in ROS levels instead 




1.2.9.3. Flavonoids and mitochondria 
An inability to accumulate into mitochondria may explain the lack of activity of some 
antioxidants. Mitochondriotropic compounds may overcome this limitation and several studies 
suggest the ability of some flavonoids to accumulate into isolated mitochondria (Cavallini et al, 
1978; Dragicevic et al, 2011; Haraguchi et al, 1996; Trumbeckaite et al, 2006) and mitochondria 
of cultured cells (Dragicevic et al, 2011). Their accumulation was associated with reductions in 
lipid peroxidation following exposure to of isolated mitochondria to pro-oxidants (eg. Elingold et 
al, 2008; Santos et al, 1998; Ratty and Das, 1988). Also, flavonoids were able to inhibit membrane 
permeability transition in Ca2+ induced mitochondrial swelling and inhibition of protein sulfhydryl 
oxidation (Santos et al, 1998). Some flavonoids were also able to inhibit NADH-oxidase activity 
in mitochondria which may inhibit ROS generation (Hodnick et al, 1994; Santos et al, 1998). 
Several flavonoids such as quercetin and epicatechin, cooperate with ascorbate to protect 
mitochondria-mimetic membranes from cytochrome c-catalyzed lipid peroxidation (Bandy and 
Bechara, 2001). Although the accumulation of quercetin in mitochondria was found to be 
significant in vitro (Fiorani et al, 2010; Mattarei et al, 2008) it is not clear whether quercetin 
accumulates in sufficient quantities in tissue mitochondria, particularly in the heart, to protect cells 
from mitochondrial insults (de Oliveira et al, 2016). Apart from the work of Peng (2012), the 
intracellular distribution of cyanidin has not been evaluated.  
1.2.9.4. Anthocyanins  
Anthocyanins are flavonoids found in fruits and vegetables as water soluble glucosides of 
polyhydroxy and polymethoxy derivatives of 2-phenylbenzopyrylium or flavylium salts (Figure 
1.4) (Wallace, 2013). The glucosylated or nonglucosylated forms are named anthocyanins and 
anthocyanidins, respectively (Figure 1.4). They act as natural pigments in plants and give them 
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their blue, purple, and red colors. Six anthocyanins are largely found in nature, namely, glucosides 
of the anthocyanidins cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin. The wide 
range of compounds differs in the number and location of hydroxyl, methylated and glucoside 
groups. These chemicals have attracted considerable interest for their potent antioxidant activity 
when tested in many different in vitro and in vivo assays (Andres-Lacueva et al, 2005; Hassimotto 
et al, 2008; Neto, 2007; Serraino et al, 2003). Previous studies in our laboratory (Peng, 2012) 
suggest that their potential favourable activity compared to other flavonoid subclasses is most 
likely caused by their accumulatation in mitochondria where they can exert their antioxidant 
activity.   
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OH  OH  Delphinidin-3-glucoside  
(Delphin)  
OH  OH  Delphinidin  
OCH3  OH  Petunidin-3-glucoside  
(Petunin)  
OCH3  OH  Petunidin  
OCH3  OCH3  Malvidin-3-glucoside  
(Malvin)  
OCH3  OCH3  Malvidin  
Figure 1.4: General structure of anthocyanins. The presence and location of the different 
functional groups forms the wide variety of anthocyanin compounds (Adapted from Sancho and 
Pastore, 2012).   
 
1.2.9.4.1. Anthocyanins and mitochondria  
Since the involvement of mitochondrial ROS is apparent in many diseases and conditions, 
targeting this organelle by antioxidants is crucial. However, achieving an ideal antioxidant with 
potential treatment activity has been a challenge. The chemical structure should have sufficient 
lipophilicity and a positive charge at physiological pH (Graham et al, 2009). Interestingly, both 
structural features are found in anthocyanidins. Therefore, these compounds are presented as a 
widely available and inexpensive antioxidant. The antioxidant activity and the therapeutic 
potential of anthocyanins have been well documented (Lila 2004; Prior et al, 2001; Zhao et al, 
2013; Zheng et al, 2003). Work from our laboratory (Peng, 2012) showed that the anthocyanidin, 
cyanidin, accumulated in the mitochondria to a greater extent than cyanidin-3-glucoside, quercetin 
and quercetin-3-glucoside. Being widely available, these compounds might serve as an 
inexpensive alternative to synthetic mitochondriotropic antioxidants and have therapeutic benefit 
in conditions such as doxorubicin-induced mitochondrial damage in the heart.  
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The attraction of amphiphilic compounds such as anthocyanidins into the mitochondria 
may be influenced by the mitochondrial membrane potential (MMP). This charge is believed to 
increase the accumulation of lipophilic cations inside the mitochondria by 10 fold for every 61 mV 
increase (Murphy, 2008). In addition to the MMP, the unique phospholipid cardiolipin, found in 
large quantities in the inner mitochondria membrane (Houtkooper and Vaz, 2008) possesses a 
negative charge (Paradies et al, 2014), which further facilitates the accumulation of lipophilic 
cationic compounds.   
Flavonoids differ in their pKa value which determines the charge they possess at 
physiological pH. A suitable pKa is required to enable the flavonoids to form a positive charge 
thus allowing their accumulation in the mitochondria. With pKa values for anthocyanin flavylium 
ions of 5.3-5.9 (Borkowski et al, 2005), the equilibrium between the different forms of cyanidin 
favors the formation of flavylium cation along with the neutral quinoid form at physiological pH 
(Figure 1.5). With regard to C3G however, the highly hydrophilic glucoside molecule attached 
to the anthocyanidin may impede its entrance to the mitochondria. Therefore, the aglycone 
possesses the favorable charge with reasonable lipophilicity to passively cross the mitochondrial 
membrane. This may present an explanation for the higher cytoprotective activity for cyanidin 
compared to C3G against doxorubicin-induced cytotoxicity and lipid peroxidation observed 
previously in H9c2 cardiomyocytes (Choi et al, 2007) and against different pro-oxidants in other 
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Figure 1.5: Proposed degradation pathway for anthocyanins. Cyanidin parent compound, 
flavylium ion (287 Da), is speculated to degrade rapidly to protocatechuic acid (PCA) (154 Da) 
and phloroglucinaldehye (PGA) (154 Da) by passing through different intermediate compounds 
namely, hemiketal (304 Da), chalcone (304 Da). Quinoidal base (286 Da) is also proposed as a 
product of the degradation. 99% of the compound is assumed to be found in the indicated form at 
the indicated pH.  (Adapted from Borkowski et al, 2005; Fang, 2014; Kamiloglu et al, 2015).   
 
 In contrast, the subclasses, flavonols and flavanols with pKa’s of ~6 and ~4, respectively 
(Escandar and Sala, 1991; Lemanska et al, 2001; Jovanovic et al, 1994), would form a mixture of 
anions and neutral molecules at neutral pH. Despite their known strong antioxidant potency, 
relative stability and amphiphilic nature, the negatively charged flavonoids at physiological pH 
(quercetin, catechin) (Chebotarev and Snigur, 2015) may have less mitochondrial uptake and 
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activity compared to cyanidin. Despite these favourable structural features, anthocyanidins 
including cyanidin are believed to have low systemic bioavailabilities, which may cause a limited 
clinical outcome. However, should the low quantities of an anthocyanidin accumulate in key 
organelles (such as the mitochondrial inner membrane), it could have substantial biological effects.  
1.2.9.4.2. Systemic exposure following oral or IV administration  
 Anthocyanins, particularly C3G, are rapidly and directly absorbed across the intestine 
causing a fast increase in plasma levels (Hassimotto et al., 2008; Mazza et al., 2002) but only to 
reach a low plasma bioavailability (0.02%) (Abourashed, 2013; de Ferrars et al, 2014) with a low 
plasma half-life (t1/2 0.36 h) (Czank et al, 2013; de Ferrars et al, 2014; Fang, 2014; Prior et al, 
2010; Seeram et al, 2001; Tsuda et al,  2000; 1999; Vanzo et al, 2011; Vitaglion et al, 2007). The 
low bioavailability is often assumed to be due to rapid degradation in physiological environments 
(McGhie and Walton, 2007; Wallace and Giusti, 2013), as observed in many in vitro experiments 
(Kay et al, 2009; Liu et al, 2014b; Yang et al, 2018). However, some studies suggest that they 
may be more bioavailable than previously thought (Kay et al, 2017; Lila et al, 2016). Despite 
these reports, observations from in vivo work provide some evidence that C3G, once introduced 
to the blood, does not immediately degrade to PCA and PGA. For example, the fast disappearance 
of anthocyanins from plasma is accompanied by the fast appearance of C3G/anthocyanins in 
brain, kidney, liver and urine after an oral ingestion (Bub et al, 2001; de Ferrars et al, 2014; Kalt 
et al, 2008; McGhie and Walton, 2007, Matsumoto et al., 2001; Mazza et al, 2002; Talavera et al, 
2005; Vanzo et al, 2011). Also, limitations in available analytical techniques have possibly 
resulted in underestimation of the stability of anthocyanins (Lila et al, 2016). Additionally, one 
group (Peng, 2012) were able to detect cyanidin in the heart of injected mice 30 min after its 
administration. Combined, these reports provide evidence that anthocyanins and possibly 
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anthocyanidins do not degrade immediately after administration. Therefore, further research on 
their stability is needed in different in vitro settings which might be extrapolated to in vivo 
physiological environments.  
1.2.9.4.3. Anthocyanin stability in in vitro physiological environments 
Few studies have addressed the stability of anthocyanins in different in vitro settings 
relevant to biological activities (Kay et al, 2009; Kern et al, 2007; Seeram et al, 2001). A series 
of degradation experiments for cyanidin and C3G in different environments were performed (Kay 
et al, 2009). In summary, a loss of ~15% and ~90% of original C3G and cyanidin, respectively 
were reported within 3 h when incubated in phosphate buffered saline (PBS) (37°C, pH 7.4). The 
major degradation products detected were PCA and PGA. The degradation process is speculated 
to pass through many intermediate chemicals leading to the two compounds (Figure 2.5) (Fang, 
2014). The production of PCA and PGA is presumed to occur rapidly and irreversibly (Fang, 
2014; Kay et al, 2009). A similar lack of stability in cell culture media was also observed by other 
groups (Kern et al, 2007; Seeram et al, 2001). Such studies have led to a general belief that the 
bioactivity of dietary anthocyanins is likely to be mediated by their degradation products 
particularly, PCA and PGA (Kay et al, 2009).  
1.2.9.4.4. Biological activity of Anthocyanins  
 Anthocyanins may exert their biological activity as ROS scavengers (Chun et al, 2003, 
Wallace and Giusti, 2013). In addition to their antioxidant activity, some anthocyanins such as 
cyanidin have strong anti-inflammatory activity. Indeed, cyanidin showed higher potency against 
cyclooxygenase activity than the relatively potent anti-inflammatory drugs naproxen, ibuprofen 
and aspirin (Wang et al, 1999). In addition, a few anthocyanins were reported to protect DNA 
from oxidative damage (Sarma and Sharma, 1999) by forming a stabilized DNA triplex (Mas et 
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al, 2000). Anthocyanins may also preserve the activity of GSH and inhibit cardiolipin oxidation 
and mitochondrial fragmentation in certain neuronal cells (Kelsey et al, 2011). Due to these 
activities, anthocyanins may be able to exert many health benefits (Tsuda et al, 1999; Tsuda 
2012).   
1.2.9.4.5. The cytoprotective effects of anthocyanins against ROS related diseases  
 Due to their antioxidant activity, anthocyanins may protect from many diseases related to 
ROS such as cancer (chemotherapeutics), Parkinson’s disease, microbial infections, inflammatory 
diseases, ocular and cardiovascular diabetic complications, and neurodegenerative disorders (Al-
Awwadi et al, 2005; Chen et al, 2005; Dai et al, 2009; Kong et al, 2003; Mazza et al, 2002; Mink 
et al, 2007; Nasri et al, 2011; Neto, 2007; Olsson et al, 2004; Sasaki et al, 2007; Thomasset et al, 
2009; Tsuda et al, 2003). In addition, the protective ability of anthocyanin-rich extracts against 
doxorubicin-induced ROS to mitigate its cardiotoxicity has been investigated mostly by in vitro 
(Hosseini et al, 2017; Tenore et al, 2013) and a few in vivo (Ashour et al, 2011; Choi et al, 2010; 
Diamanti et al, 2014; Hassanpour et al, 2011) studies. The use of extracts in these studies limits 
the ability to identify the causative bioacitive compound(s). Two studies have shown the protective 
effect of pure anthocyanidins or an anthocyanin-rich extract against doxorubicin-induced oxidative 
damage in H9c2 cells (Choi et al, 2007; Huang et al, 2016). However, to our knowledge, the 
protective activity of anthocyanins has not been compared with other subclasses of flavonoids to 
highlight the importance of their structural features (i.e. positive charge and suitable lipophilicity). 
1.2.10. The usage of antioxidants with cancer chemotherapeutics                                                                                                                                
 Elevated ROS is important in cancer cell proliferation and survival (Kumari et al, 2018; 
Liou and Storz, 2010). Therefore, depleting their concentration by antioxidants can inhibit cancer 
cell proliferation (Dong et al, 2016; Zhang et al, 2016). Therefore, antioxidants have been 
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employed for the purpose of lowering ROS levels to inhibit cancer cell proliferation. However, a 
concern stems from the ability of cancer cells to produce further ROS thus limiting the 
effectiveness of the antioxidants. Although promising, evidence for the effectiveness of 
antioxidants in cancer treatment, are limited (Seeram et al, 2006; Simone et al, 2007; Singh et al, 
2018; Yang et al, 1998).  
In addition, when used with chemotherapeutics, antioxidants have been shown to protect 
different cell types from the toxicity of the drugs (Singh et al, 2017). ROS-induction by some 
chemotherapeutics is involved in their mechanism of cytotoxicity in cancer cells (Alexandre et al, 
2006; Llobet et al, 2008; Qanungo et al, 2005; Shankar et al, 2008; 2007; Yokoyama et al, 2017). 
Consequently, antioxidants might lower ROS levels and ‘protect’ these cells from 
chemotherapeutics. Collectively, the use of antioxidants in cancer therapy with or without 




1.3. HYPOTHESIS AND OBJECTIVES  
Our interest in anthocyanidins is rationalized by their potential ability to accumulate into 
mitochondria enabling them to exert a potent antioxidant effect comparable to that of known 
antioxidants such as vitamin E, ascorbic acid and β-carotene (Kowalczyk et al, 2003; Rice-Evans 
et al, 1996; Wang et al, 1999) and to other flavonoid subclasses (Rice-Evans et al, 1996). Of the 
many different anthocyanidins, cyanidin has gained considerable interest for its potent antioxidant 
ability compared to other members of the subclass (Choi et al, 2007; Khoo et al, 2017). Also, the 
paradox between cyanidin’s enhanced bioactivity and its limited stability warrants further 
investigation into factors influencing its stability and degradation.   
1.3.1. Hypotheses 
1) Cyanidin provides the strongest antioxidant and cytoprotective ability against a mitochondrial 
insult (doxorubicin) in cardiomyocytes compared to its glucosylated form (C3G), quercetin 
(flavonol) and catechin (flavanol).  
2) Reduction in cardiomyocyte toxicity is caused by parent compound, intermediate compounds, 
and breakdown products, PCA and PGA.  
3) Cyanidin will accumulate to a greater extent into mitochondria of cardiomyocytes than C3G, 
quercetin and catechin. 
4) Cyanidin will not interfere with the cytotoxic effect of doxorubicin against cancer cells.  
5) Cyanidin does not degrade immediately when dissolved in physiological solutions. 
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1.3.2. Objectives  
Objective one: Measure the protective effect of cyanidin and its metabolites, C3G, quercetin and 
catechin against doxorubicin-induced cytotoxicity in differentiated H9c2 cells using the SRB and 
MTT assays.  
Objective two: Identify the mechanism(s) by which doxorubicin causes cytotoxicity and how 
flavonoids exert their cytoprotective activity against doxorubicin in differentiated H9c2 cells. 
Objective three: Demonstrate the mitochondrial accumulation of cyanidin in differentiated H9c2 
cells. 
Objective four: Determine if cyanidin enhances or inhibits the cytotoxicity of doxorubicin against 
K562 and HepG2 cell lines. 
Objective five: Evaluate the stability and breakdown of cyanidin in different biological fluids, 




CHAPTER TWO: METHODOLOGY 
 
 
2.1. MATERIALS AND CELL LINES  
Human hepatoma (HepG2) and myelogenous leukemia (K562) cell lines were a kind gift 
from Drs. Dimmock and Wasan, respectively. The rat cardiomyoblast (H9c2) (CRL-1446) cell 
line was purchased from American Type Culture Collection (ATCC®, Manassas, VA). Fetal 
bovine serum (FBS) (12-483-020) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide  (MTT) (298-93-1) were purchased from Thermofisher® (Waltham, MA). DMEM/High 
Modified (SH30604.01) RPMI-1640 medium (SH30255.01), PBS (SH30256.01) and trypsin 
0.25% (SV30031.01) were purchased from HyClone (South Logan, UT). Human serum off-clot 
(823192) was purchased from BM biochemical (Santa Ana, CA). Protocatechuic acid (PCA) 
(0393-05-90) was purchased from HWI Analytik BmbH (Rulzheim, Germany). Doxorubicin 
(15007) was purchased from Cayman Chemical (Ann Arbor, MI). Penicillin-streptomycin 
(A5955), catechin (C1251), quercetin (Q4951), 2,4,6-trihydroxybenzaldehyde 
(phloroglucinaldehyde) (PGA) (T65404), (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) (H3375), sulforhodamine B (S1402) and dimethyl sulfoxide (DMSO) (0909S) were all 
purchased from Sigma-Aldrich (St. Louis, MO). Cyanidin (0909S) and kuromanin (C3G) (0915S) 
were both purchased from Extrasynthese (Genay, France). 18 megaΩ milliQ water was used in 
sample preparations. Protocatechuic acid (PCA) (0393-05-90) was purchased from HWI Analytik 
BmbH (Rulzheim, Germany). Doxorubicin (15007) was purchased from Cayman Chemical (Ann 




2.2. PROTECTION AGAINST DOXORUBICIN-MEDIATED CYTOTOXICITY OF 
DIFFERENTIATED H9C2 CELLS BY CYANIDIN, QUERCETIN, CATECHIN AND 
C3G. 
One of our objectives was to determine the cytoprotective effects of cyanidin and the other 
flavonoids against doxorubicin-mediated cytotoxicity. To achieve this, we initially determined the 
concentration- and time-dependent effects of doxorubicin on cell survival, mitochondrial functions 
(MTT and MMP assays), intracellular ROS generation, mitochondrial superoxide generation, and 
cellular morphology. These determinations were followed by the evaluation of the ability of 
flavonoids to protect against doxorubicin-induced changes. 
2.2.1. H9c2 culture and differentiation  
H9c2 cells were stored in liquid nitrogen until required. Passages 4-6 were used throughout 
all experiments. Undifferentiated H9c2 cells were cultured in T75 flasks (Corning®, NY) in 15 
mL of their recommended growth medium, DMEM/high glucose supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin-streptomycin (PEN/STREP), and left overnight to attach 
(37°C, 5% CO2). The medium was changed every second day until confluency was reached.   
For differentiation, the existing medium was removed, and differentiation medium was 
added to cells for 7 days. DMEM/High glucose supplemented with 1% FBS, 1% penicillin and 1 
nM retinoic acid was used as the differentiation medium (Branco et al, 2012). The medium was 
changed on days 3 and 6. Changes in the morphology of the cells was monitored throughout the 7 
days to confirm the differentiation. Undifferentiated cells appeared mononucleated and spindle in 
shape (Kimes and Brandt, 1976), while differentiated ones were long and multinucleated with thin 




2.2.2. Detection of cell survival using the sulforhodamine B assay  
Cytotoxicity was measured using the sulforhodamine B (SRB) assay (Orellana and 
Kasinski, 2016; Vichai and Kirtikara, 2006). This assay quantitates the amount protein present in 
wells and assumes a correlation with cell viability at the time of the assay. A stock solution of SRB 
was prepared in 1% acetic acid at a concentration of 0.5 mg/mL. The SRB assay was initiated by 
fixing the adherent cells with the addition of 100 µL of 20% trichloroacetic acid (TCA) to the 
existing 100 µL medium in each well with adherent cell lines. This was followed by incubation 
for one hour at 4°C. Non-adherent cells required the addition of 60% TCA for 2 h at the same 
temperature (Kim et al, 1996). The TCA fixed cells were washed with tap water and left to air dry. 
100 µL of stock SRB solution was then added and left to incubate for 30 min at room temperature. 
Cells were washed with 1% acetic acid to allow the binding of SRB to the protein and to remove 
unbound dye. Cells were allowed to air dry. 200 µL of 10 mM Trizma base (pH 10) was added to 
each well to dissolve the bound dye. A Biotek plate reader (Winooski, VT) was used to detect the 
absorbance of SRB at 510 nm. The percentage of adherent cell protein in treated wells was 
referenced to the control wells for determination of percentage of cell survival.  
Percentage of cell survival = 100 – (
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒(𝑐𝑜𝑛𝑡𝑟𝑜𝑙)−𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 X 100 )  
2.2.2.1. Evaluation of cytotoxicity of doxorubicin in differentiated H9c2 cells 
The IC50 value was initially calculated to establish an idea of the toxicity of doxorubicin 
against differentiated H9c2 cells and to determine the appropriate concentrations for usage in 
subsequent assays. 1.0104 H9c2 cells were seeded in a 96-well plate and allowed to differentiate 
for 7 days (Section 2.2.1). The cells were then exposed to different concentrations of doxorubicin 
in the range of 0.1 - 10 µM (with a final concertation of DMSO less than 0.05%) for 24 h. Once 
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the exposure period was complete, the SRB assay was initiated to determine the adherent cell 
density (Section 2.2.2).  
The change in cell morphology after incubation with doxorubicin was also detected by 
imaging using a ZOE microscope. Differentiated H9c2 cells were exposed to doxorubicin (1 µM) 
(DMSO less than 0.05%) in differentiation medium. Wells with differentiation medium without 
doxorubicin (with similar DMSO percentage) were used as a negative control. Since doxorubicin 
is known to cause cytotoxicity, no positive control was needed. Cells were imaged after 3, 6, 12 
and 24 h of incubation. Several images were taken at each time. Plates were returned to the 
incubator until the next specific period of incubation. The same wells were imaged after each time 
to record the change in cell number and morphology with time.   
To further understand the cytotoxic behaviour of doxorubicin on cardiomyocytes, 1.0104 
H9c2 cells were seeded in each well in a 96-well plate and allowed differentiate as per Section 
2.2.1. Differentiated H9c2 cells were incubated with 1 µM of doxorubicin for 3, 6, 12 and 24 h or 
5 µM for 3 and 6 h in differentiation medium (DMSO less than 0.05%). Cell survival was then 
measured using SRB assay immediately after the exposure period or after a further 24 h incubation 
in fresh differentiation medium. Wells with cells in differentiation medium without doxorubicin 
(with similar DMSO percentage) were used as a negative control. Since doxorubicin is known to 
cause cytotoxicity, no positive control was needed.  
2.2.2.2. Evaluation of the effects of cyanidin with doxorubicin on cell survival in 
undifferentiated H9c2 cells 
 Undifferentiated H9c2 cells were first used to confirm the protective activity of cyanidin 
against doxorubicin as reported previously (Choi et al, 2007). 1.0104 undifferentiated H9c2 cells 
were seeded in a 96-well plate in their respective growth medium (100 µL) (DMEM/high glucose-
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HyClone) supplemented with 10% FBS and 1% PEN/STREP and left over night to attach (37°C, 
5% CO2). The cells were then exposed to doxorubicin (1 µM) alone for 24 h (DMSO less than 
0.05%). Doxorubicin was then removed and fresh medium containing cyanidin (50 or 100 µM) 
was added for another 24 h (DMSO less than 0.4 %). The percentage of cell viability was then 
assessed as detailed in the SRB assay (Section 4.2.2.). Control wells also received vehicle (<0.05% 
DMSO) treatments.  
2.2.2.3. Evaluation of the effects of flavonoids with doxorubicin on cell survival in differentiated 
H9c2 cells 
The detection of doxorubicin’s cytotoxicity against differentiated H9c2 cells was followed 
by determination of the cytoprotective effects of the flavonoids against doxorubicin-mediated 
cytotoxicity.  For this purpose, different treatment patterns were used to assess the cytoprotective 
effects. 1.0104 H9c2 cells were seeded in a 96-well plate and differentiated for 7 days (Section 
2.2.1.). Differentiated cells were then subjected to different patterns of treatments followed by the 
SRB assay to determine percentage of cell viability. Throughout all patterns used, DMSO never 
exceeded 1.2%. Control wells also received vehicle (<0.05% DMSO) treatments. The different 
treatment patterns are explained: 
A) Co-treatment: This experimental design was used to explore if cyanidin is able to protect 
differentiated H9c2 cells from direct and immediate (rather than delayed) cytotoxicity of 
doxorubicin. Differentiated H9c2 cells were incubated with 100 µL of the differentiation medium 
containing doxorubicin (1 µM) with or without cyanidin (50 or 100 µM) for 24 h at 37°C and 5% 
CO2 (DMSO was less than 0.05%). Control wells received only equivalent amounts of medium 
with DMSO. After 48 h cytotoxicity was determined using the SRB assay.  
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B) Pre/co-treatment: This experimental setting was conducted to verify if co-treatment with 
cyanidin, starting 1 h prior to doxorubicin exposure (to allow intracellular loading of cyanidin) 
was able to protect differentiated H9c2 cells from cytotoxicity of doxorubicin. Differentiated H9c2 
cells were initially incubated with 100 µL of differentiation medium containing cyanidin (50 or 
100 µM) (DMSO less than 0.4%) for 1 h (at 37°C and 5% CO2). This was followed by the addition 
of doxorubicin (1 µM) (4 µL of 25 µM) to the same medium (total DMSO less than 0.5%). Both 
treatments were incubated together for 24 h at 37°C and 5% CO2. Some wells received only 
doxorubicin treatment to assess the protective ability of cyanidin. Control wells received only 
equivalent amounts of medium with DMSO. Cytotoxicity was determined using the SRB assay. 
C) Multiple treatments of cyanidin: This experimental setting was conducted to verify if cyanidin 
pulses are able to protect differentiated H9c2 cells from direct cytotoxicity of doxorubicin. 
Differentiated H9c2 cells were treated with doxorubicin (1 µM) and cyanidin (10 µM) and left to 
incubate in differentiation medium for 24 h. While doxorubicin (1 µM) was added only once, 
cyanidin was added every 8 h for 24 h (total of 3 additions) (at 37°C and 5% CO2) (DMSO equalled 
1.2%). The treatments were added with 100 µL of differentiation medium. Some wells received 
only doxorubicin. Control wells received only equivalent amounts of medium with DMSO. 
Cytotoxicity was determined using the SRB assay. 
D) Co-treatment and delayed assessment: This experimental setting was conducted to verify if 
cyanidin is able to immediately protect differentiated H9c2 cells from the rapid cytotoxicity caused 
by doxorubicin but observed at a delayed time. Differentiated cells were incubated with 
doxorubicin (1 µM) with or without cyanidin (50 or 100 µM) in 100 µL differentiation medium 
for 24 h. Both treatments were replaced by 100 µL fresh DMEM containing no treatments. The 
cells were incubated for another 24 h followed by the initiation of SRB assay. A similar procedure 
36 
 
was also followed using C3G, catechin and quercetin. Control cells received only medium on the 
first 24 h followed by its replacement with another batch of fresh medium.  
E) Post-treatment: This experimental setting was conducted to verify the ability of cyanidin to 
protect differentiated H9c2 cells from delayed cytotoxicity of doxorubicin. Differentiated cells 
were incubated with 100 µL of differentiation medium containing doxorubicin (1 µM) treatment 
alone for 24 h. This was followed by the removal of the treatment and the addition of 100 µL 
DMEM/high glucose-HyClone fresh medium containing cyanidin (50 or 100 µM). Doxorubicin-
containing medium was switched to differentiation medium containing no cyanidin to assess the 
protective activity. Control cells received only medium for the first 24 h followed by its 
replacement with another batch of fresh medium. Cytotoxicity was determined using the SRB 
assay. The same procedure was also followed using C3G, catechin and quercetin.    
2.2.3. Determination of cell viability by the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide (MTT) assay  
The MTT assay measures the activity of mitochondrial reductases which reflects 
mitochondrial energy metabolism level (Mosmann, 1983). H9c2 cells were seeded at 1.0104 cells 
per well in a 96-well plate in DMEM (supplemented with 10% FBS and 1% penicillin-
streptomycin) and left overnight to attach. A stock solution of MTT was first prepared in the 
medium at a concentration of 5 mg/mL. After the treatment period was complete, 20 µL MTT 
solution was added to each well (1 mg/mL final concentration) and left to incubate for 3 h at 37°C. 
The medium was then removed and 200 µL of DMSO was added to each well to dissolve the 
formazan crystals. Absorbance was then measured for each well at 570 nm using a plate reader 




2.2.4. Evaluation of the effects on intracellular ROS  
For measurements of intracellular ROS, H9c2 cells were plated in a black 96-well plate 
with a transparent bottom at 1.0104 cells/well, and allowed to differentiate for 7 days (Section 
4.2.1.). The cells were then treated with 1 µM of doxorubicin for 0.5, 1, 3, 6, 12 or 24 h or 5 µM 
for 30 or 60 min (37°C and 5% CO2). In addition, to measure of the protective effects of the 
flavonoids against the observed doxorubicin-induced increase in ROS, cells were treated with 
doxorubicin (1 µM) with or without a flavonoid (cyanidin, quercetin, catechin or C3G) (100 µM) 
for 12 or 24 h. The incubations were followed by the measurement of intracellular ROS levels 
using 2'-7'-dichlorodihydrofluorescein diacetate (DCFH-DA) dye. The treatments were removed 
and the cells were washed once with fresh medium. The dye was added at a concentration of 5 
mg/mL in DMEM (without phenol red) for 30 min. The fluorescence produced was detected at 
excitation and emission wavelengths of 485 and 528 nm, respectively, using a plate reader (Biotek 
Instrument, Winooski, VT). When indicated, the SRB assay was initiated immediately after 
measuring the fluorescence intensity of DCF. The fluorescence intensity measured for a certain 
well was normalized to the absorbance value measured after the completion of the SRB assay for 
the same well.   
2.2.5. Evaluation of the effects on mitochondrial superoxide  
This experiment was conducted to determine the conditions at which doxorubicin induced 
an immediate and delayed increase in mitochondrial superoxide. The experiment was initiated by 
seeding H9c2 cells in a black 96-well plate and allowing their differentiation similar to Section 
2.2.1.  Differentied 1.0104 H9c2 cells per well (in a black 96-well plate with transparent bottom) 
were incubated with doxorubicin at a concentration of either 1 µM for 0.5, 1, 3 and 6 h or 5 µM 
for 30 min (37°C and 5% CO2). Differentiated cells were also treated with doxorubicin of a specific 
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concentration (1 µM) with or without a flavonoid (cyanidin, quercetin, catechin or C3G) (100 µM) 
in 100 µL differentiation medium for 3, 6 or 12 h. After incubation, the cells are washed once with 
DMEM medium. MitoSOX was dissolved in DMEM (without FBS and without phenol red) at a 
final concentration of 5 µM (100 µL) and loaded to each well. The plate was incubated for 30 min 
at (37°C and 5% CO2). The wells were then washed twice with 100 µL PBS. 100 µL of PBS were 
added to each well followed by the measurement of the fluorescence intensity at excitation and 
emission wavelengths of 530 and 590 nm, respectively, using a plate reader (Biotek Instrument, 
Winooski, VT). After the measurement of mitochondrial superoxide generation, the SRB assay 
was initiated by the addition of 100 µL TCA (20%) to each well which also contained 100 µL 
PBS. When indicated in the results, the fluorescence value from each well was normalized to the 
SRB value of the same well. 
2.2.6. Evaluation of the effects on mitochondrial membrane potential (MMP)  
This experiment was conducted to determine if doxorubicin had an immediate and/or a 
delayed effect on MMP. H9c2 cells were seeded in a black 96-well plate and allowed to 
differentiate as in Section 2.2.1. The cells were incubated with doxorubicin at a concentration of 
either 1 µM for 3, 6 and 12 h or 5 µM for 30 min (at 37°C). These experiments were also followed 
by measurements to determine the protective effects of the flavonoids (cyanidin, quercetin, 
catechin and C3G) against doxorubicin’s effects on MMP. Cells were treated with doxorubicin (1 
µM) with or without the tested flavonoid (100 µM) for 12 h in differention medium. The incubation 
was followed by the measurement of MMP levels using tetramethylrhodamine ethyl ester (TMRE). 
The treatments were removed and the cells were washed once with 200 µL of DMEM. TMRE dye 
was added to the cells at a concentration of 5 µM in DMEM (without phenol red) and incubated 
for 30 min. The cells were washed twice with 100 µL PBS. PBS (100 µL) was then added to each 
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well followed by the measurement of the fluorescence at excitation and emission wavelengths of 
500 and 590 nm, respectively, using a plate reader (Biotek Instrument, Winooski, VT). After the 
measurement, cells were fixed by the addition of 100 µL TCA (20%) to each well for 1 h at 4°C 
followed by the conduction of SRB assay (Section 4.2.2.). When indicated, the fluorescence value 
for TMRE from each well was normalized to the SRB value of the same well.  
2.2.7. Determination of mitochondrial morphology using electron microscopy (EM) 
The effect of doxorubicin on the morphology of the mitochondria in H9c2 was previously 
determined using electron, confocal and light microscopy (Jakobs et al, 2011; Sardao et al, 2009). 
We used EM to determine the ability of cyanidin to inhibit the detrimental effects of doxorubicin 
on mitochondrial morphology. 5.0105 H9c2 cells were plated in a T25 flask using DMEM and 
allowed to differentiate for 7 days (Section 4.2.1.). Flasks were divided into four groups. Flask one 
received doxorubicin (1 µM) with cyanidin (100 µM) and left to incubate for 24 h. The medium 
was then removed, fresh differentiation DMEM containing no doxorubicin or cyanidin was added 
and the cells were left to incubate for another 24 h. Flask two received only doxorubicin and the 
cells were left to incubate for 24 h. The DMEM containing the agent was removed and replaced 
by differentiation DMEM containing cyanidin (100 µM). The cells were then incubated for 24 h. 
Flask three received only differentiation DMEM containing doxorubicin (1 µM) for 24 h. After 
the removal of the medium, fresh differentiation DMEM was added and the cells were left to 
incubate for 24 h. Flask four (control) received no treatment but the medium was replaced after 24 
h with fresh media.  
Once the treatment periods were over, the DMEM was removed and cells were washed with 
FBS-free DMEM medium. Cells were fixed using 2% glutaraldehyde in 0.1 M sodium phosphate 
buffer (pH 7.2) for 4 h at 4°C. Some cells started to float by this step, however, scraping was 
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required to ensure the detachment of most cells. The cells were taken into a 1.5 mL tube and 
centrifuged at 1000 RPM for 2 min. The fixative liquid was removed and the pellet was washed 4 
times with 0.1 M sodium phosphate buffer. The pellet was sent to the Western College of 
Veterinary Medicine Imaging Centre for further processing and EM imaging. 
2.3. EFFECTS OF CYANIDIN AND QUERCETIN ON DOXORUBICIN 
CYTOTOXICITY IN HEPG2 AND K563 CELL LINES  
2.3.1. Culturing HepG2 and K562 cells.  
HepG2 and K562 were cultured in DMEM/high glucose-HyClone supplemented with 10% 
FBS and 1% PEN/STREP using T75 flasks. HepG2 cells were left overnight to attach (37°C, 5% 
CO2) and medium was changed every second day until confluency. The K562 cells, which are 
nonadherent, were left overnight to grow. 2-3 mL of medium was added to the culture every 3 
days until the cells were highly dense. HepG2 cells were subcultured by trypsinizing the cells and 
dividing them to 3-4 new flasks. Cells were then left to attach overnight. K562 cells present in 10-
12 ml medium were subcultured by their transfer to a 50 ml falcon tube followed by centrifugation 
to form a pellet. The supernatant (old medium) was replaced by a fresh medium (20 ml). The 
volume was then split to 2-3 T75 flasks (around 6-7 ml per flask). All experiments were conducted 
with passages 10-15.  
2.3.2. SRB assay to determine the cytotoxicity against HepG2 and K562 cells                  
The IC50 value was initially calculated to establish an idea of the toxicity of doxorubicin 
against HepG2 cells in addition to establishing the appropriate concentrations for use in subsequent 
assays. 1.0104 HepG2 cells per well were seeded in a 96-well plate using normal DMEM and left 
overnight to attach. Cells were then exposed to different concentrations of doxorubicin in the range 
of 0.000305–20 µM for 72 h. A similar procedure was followed using K562 cells. However, they 
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were seeded at 5.0104 cells per well and left to incubate over night at 37°C to attach. Cells were 
then incubated with doxorubicin (1 µM) with or without a flavonoid (cyanidin or quercetin) at 
concentrations of 50 or 100 µM for 72 h. The flavonoids were added either one time (single 
treatment) or every 24 h for 72 h (multiple treatments). After the completion of a treatment 
condition, the SRB assay was conducted as detailed in Section 3.1.2 to quantify cell viability of 
HepG2. A simiar SRB procedure was also followed for K562 cells except the requirement of a 
centrifugation step at 1200 RPM for 5 min before the removal of medium from each well and the 
incubation with 60% TCA (prepared in water) for 2 h at 4°C (Kim et al, 1996).  
2.3.3. (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) (MTT) assay using 
HepG2 and K562 cells.  
MTT was used to detect if the cytotoxicity is preceded by changes in metabolism activity. 
1.0104 cells HepG2 cells were seeded in a black 96-well plate and left to attach overnight as 
detailed in Section 2.2.6. Cells were then exposed to 1.5 µM doxorubicin with or without cyanidin 
or quercetin 50 or 100 µM added every 24 h for 72 h. A similar procedure was followed for K562 
cells. However, they were seeded at 5.0104 cells per well and left to incubate over night at 37°C 
then exposed to 1.0 µM of doxorubicin with or without similar additions of cyanidin or quercetin. 
MTT assay was conducted as detailed in Section 2.2.3. However, K562 cells were centrifuged 
before each wash to limit the removal of cells.   
2.3.4. Measurement of MMP in HepG2 and K562 cells 
The experiment was conducted to determine if cyanidin or quercetin can potentiate the 
effect of doxorubicin on MMP in HepG2 and K562 cells. 5.0103 HepG2 cells were plated (and 
allowed to attach) in each well in a black 96-well plate (with transparent flat bottom) as detailed 
in Section 2.2.6. This was followed by treatment with doxorubicin (1 µM) with or without a 
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flavonoid (100 µM) for 24 h. 1.0104 K562 cells were also plated onto a black 96-well plate and 
allowed by the exposure to doxorubicin and a flavonoid (cyanidin or quercetin) for 12 h. Once the 
incubations were complete, the medium containing all treatments was removed. Except for the 
centrifugation of K562 cells before each wash, a procedure similar to that detailed in Section 2.2.6. 
was followed to determine MMP. 
2.3.5. Measurement of ROS in HepG2 and K562 cells 
The experiment was conducted to determine if cyanidin or quercetin can potentiate the 
effect of doxorubicin on ROS in HepG2 and K562 cells. 1.0104 HepG2 cells were plated in each 
well in a black 96-well plate as detailed in Section 2.2.4. After their attachment, the cells were 
exposed to doxorubicin (1.5 µM) with or without a cyanidin or quercetin (100 µM) for 24 h. 
Similarly, 5.0104 K562 cells were plated in a black 96-well plate. Cells were exposed to 
doxorubicin 1.0 µM with or without a similar addition of cyanidin or quercetin for 24 h. Once the 
incubation was complete, the medium containing all treatments was removed. Except for the 
centrifugation of K562 cells before each wash, a procedure similar to that detailed in Section 2.2.4. 
was followed to determine ROS.  
2.3.6. Measurement of DNA fragmentation in HepG2 and K562 cells 
 The COMET assay was conducted for quantitative determination of DNA fragmentation 
(Olive and Banáth, 2006). HepG2 or K562 (5.0104 cells) were plated in a 6-well plate and left 
overnight.  Cells were treated with doxorubicin at a concentration of 1.0 µM or 1.5 µM for HepG2 
or K562, respectively, for 72 h. Cells were then trypsinized and diluted to 10103 cells/mL with 
PBS (without any divalent ions). 400 µL of the prepared cell mixture were mixed with 1% low 
temperature melting point agarose (prepared and cooled to 40°C). The mixture was pipetted onto 
a slide and left to cool at 4°C for 2 h to ensure solidification of the gel. The slides were then 
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submerged in alkaline lysis buffer (1.2 M NaCl, 100 mM Na2EDTA, 0.1% sodium lauryl 
sarcosinate, 0.26 M NaOH (pH > 13) overnight at 4°C. The slides were then rinsed three times 
with rinsing buffer (0.03 M NaOH, 2 mM Na2EDTA (pH ∼12.3) for 20 min each at room 
temperature.  An electrophoresis was conducted at 20 Volts and 40 mA for 30 min. 0.5 µg/mL of 
DAPI solution was prepared in PBS. 200 µL of the DAPI solution was added to each slide and left 
to incubate for 5 min. A ZOE imager was used to capture the image of the DNA on the slides. 
Comet shapes containing DNA with tails and heads were formed. DNA fragmentation percentage 
was determined by calculating the ratio of the total fluorescence intensity of the tail to that of tail 
and head.         
2.4. DEGRADATION OF CYANIDIN IN DIFFERENT PHYSIOLOGICAL MEDIA  
The objective of these evaluations was the investigation of the degradation of cyanidin 
when added to physiological-like liquids (at neutral pH). These liquids include PBS (pH 7.4), the 
cell culture medium DMEM (with and without 10% FBS), human serum and HEPES buffer. The 
extent and the rate at which the parent compound degraded to PCA and PGA in physiological 
media was evaluated.  
2.4.1. Evaluation of cyanidin degradation in PBS, DMEM, human serum and HEPES 
buffer using UV-vis spectrometry 
UV-Vis spectrometry was used to determine the rate at which the absorbance of cyanidin 
changed. This provided a preliminary understanding about the rate of degradation/ transformation 
of these compounds without giving details about the nature of the products produced. All 
flavonoids were dissolved in DMSO at 25 mM and diluted to a final concentration of 100 µM in 
the different media with a final volume of 1 mL in a plastic cuvette just before UV-Vis 
measurement. Stock solutions in DMSO were stored at -80°C in 6 µL aliquots, and freshly thawed 
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just before use. Experiments were conducted in PBS (pH 7.4 and 2.4), DMEM cell culture medium 
with and without 10% FBS, human serum or 25mM HEPES buffer (pH 7.4). The experiments 
were conducted at 25°C. Initially, a complete UV-Vis (200-800nm) scan was determined for each 
sample at 0 min using a Beckman Coulter spectrophotometer. The λmax for cyanidin was recorded 
at 585 nm in all media used.  
 The determination of the rate of change in absorbance was later evaluated using a Beckman 
Coulter spectrophotometer. For these measurements, cyanidin (100 µM) was added with a cuvette 
plunger and inserted into a cuvette containing the medium. This occurred while the instrument was 
initiated to record the change in absorbance at 585 nm every 1 sec for the first 10 min. This ensured 
the detection in the change in absorbance at the very initial instant. After 10 minutes, the 
measurement of the change in absorbance at intervals of 20 min (at 25°C) was carried out. The 
recording of the changes continued until a plateau was reached at the lowest absorbance value. A 
similar procedure was followed with quercetin, catechin and C3G. However, the absorbance was 
measured at 400 nm, 280 nm and 580 nm wavelengths for quercetin and catechin, and C3G, 
respectively.    
2.4.2. Evaluation of cyanidin degradation in PBS (pH 7.4) using HPLC with UV-vis detection 
HPLC was used to provide a better understanding of the nature of the chemical 
degradation/transformation of cyanidin. The HPLC system used was from Agilent Technologies 
comprising an L-6200A pump and an L-4500 diode array detector. The analysis was performed 
using an Agilent Eclipse XDB-C18 column (150 × 4.6 mm, 5µm). All liquids used were HPLC 
grade. To determine the behaviour of cyanidin at physiological pH, HPLC was run at pH 7.4 
(mobile phases were set at 7.4). For this, a mobile phase with no FA was used. Samples were 
diluted to a final concentration of 100 µM in PBS just before injection.  
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 Cyanidin was dissolved in PBS (pH 7.4) and immediately the initial sample was injected 
onto the column (time zero). The sample injection volume was 30 µL. The remaining sample in 
PBS was left at room temperature and evaluated for degradation and product formation at different 
times. The injection was repeated at time periods of 2, 4 and 8 h. The mobile phase solvents were 
water (A) and acetonitrile (B). The mobile phase started with 10% B from 0 to 2 min.  The 
percentage of B was at 70% from 2 to 20 min. Flow rate was 1 mL min−1 and column temperature 
was 25°C.  
The presence of cyanidin flavylium ion was initially observed using the previously 
determined at λmax = 525 nm in acidic pH buffer solution (PBS pH 2.3). The λmax previously 
determined for PCA (λmax = 292 nm), PGA (λmax 315 nm) and cyanidin (λmax 585 nm) at neutral 
pH were used. Therefore, the diode array detector was set to detect the absorbance at these 
wavelengths.  
2.4.3. Degradation of cyanidin evaluated using mass spectrometry 
Samples of a stock solution were diluted to 10 µM in water with 10% methanol to ensure 
optimal ionization. Immediately after the preparation, samples were directly injected onto an 
Applied Biosystems MDS SCIEX 4000 quadrupole linear ion trap (QTRAP) mass spectrometer at 
a rate of 10 µL/min using a Hamilton syringe and Harvard syringe pump. Stock solutions of 
cyanidin dissolved in pure DMSO at 25 mM and stored at -80°C were used to make working 
solutions for the different experiments. To enhance ionization in the mass spectrometer, samples 
were prepared in LC-MS grade water (with 10% methanol) at a concentration of 10 µM. To 
determine the degradation/transformation of cyanidin, injections were repeated after various time 
points from solutions standing at room temperature. Chalcone and the hemiketal have the same 
molecular weight of 304 Da; cyanidin flavylium ion and quinoid form have molecular weights of 
46 
 
287 and 286 Da, respectively. Q1 MS negative mode using turbo spray as an ion source was used 
to detect ions at m/z 303 and 286. CUR, IS, GS1, DP and EP were set at of 10.00 V, -4500.00 V, 
14.00 psi, -60.00 V and -10.00 V. MS/MS in the negative mode with a turbo spray was used to 
determine the product ions of 303 Da. Curtain gas (CUR) and nebulizing gas (GS1) were set at 
14.0 pound per squar inch (psi) while curtain and drying gas (GS2) was set at 10.0 psi. Ion spray 
voltage (IS), declustering potential (DP) and entrance potential (EP) were set at -4500.00 volts 
(V), 6.00 V, -60.00 V, respectively. Collision energy (CE) and collision gas (CAD) were set at -
24.00 eV and 6.00 psi, respectively. MS/MS in the negative ion mode with a heat nebulizer was 
also used to perform product ion scan at m/z 153. CUR, GS1 and GS2 were set at 20.0 psi, 22.0 
psi and 15.0 psi, respectively. DP and EP were set at -60.00 V and -10.00 V, respectively. CE, 
collision cell exit potential (CXP) and CAD were set at -25.00 V, -10 V and 6.00 V, respectively. 
Temperature of ion source (TEM) and nebulizer current (NC) were set at 500.00oC and -3.00 V, 
respectively.  
2.5. MEASUREMENT OF INTRACELLULAR CYANIDIN CONCENTRATIONS  
The determination of the uptake of cyanidin by differentiated H9c2 cells was attempted. 
Different analytical methods were employed for this purpose. In order to detect the cellular uptake 
of cyanidin, determination of the optimal extraction solvent was required initially. The solvent 
characteristics were required to favour three main features of cyanidin; stability, absorptivity and 
fluorescence capability. In addition, disruption of the cell membranes was crucial to allow 
extraction from cells. Therefore, the behaviour of cyanidin in different solvents was evaluated. 
Acetonitrile (ACN) (supplemented with 0.1% formic acid (FA)), methanol (supplemented with 
0.1% FA), DMSO and PBS (supplemented with 0.1% FA and 0.1% tween-20) are solvents 
normally used for extraction purposes. 
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2.5.1. Determination of the absorptivity, stability and fluorescence characteristics of cyanidin 
in different extraction solvents. 
To determine its absorptivity, cyanidin was dissolved in acetonitrile (ACN) (supplemented 
with 0.1% FA), methanol (supplemented with 0.1% FA), PBS (supplemented with 0.1% tween-20 
and 0.1% FA) or DMSO at different concentrations. A standard curve was initially established by 
defining the absorbance as a function of the concentration. This was established by measuring the 
absorbance of cyanidin when dissolved in the different solvents at different concentrations (3.9, 
7.81, 16.62, 31.25, 62.5, 125, 250 µM). The absorbance was measured at the predetermined λmax 
(550 nm) for cyanidin in its respective solvent. Only standard curves generated with R2 above 
0.980 were accepted. The absorbance values of unknown solutions fell in the linear range of the 
standard curve. 
The stability of cyanidin was determined by dissolving it at a concentration of 100 µM in 
different solvents (namely, ACN supplemented with 0.1% FA, methanol supplemented with 0.1% 
FA, PBS supplemented with 0.1% tween-20 and 0.1% FA, or DMSO) and incubating it for 60 min 
at room temperature. The absorbance at λmax (550 nm) was measured at time zero and after 
completion of the incubation using a Biotek spectrometer plate reader (Winooski, VT). The 
percentage decrease in the absorbance was calculated.  
To determine its fluorescence behaviour in the different solvents, cyanidin was added to a 
solvent followed by measuring its excitation/emission fluorescence spectrum using a 
spectrofluorometer (PerkinElmer, LS55, Waltham, MA). Once measure, the wavelengths 
combination with the highest fluorescence intensity was further confirmed using Biotek 




2.5.2. Determination of cyanidin uptake using UV-vis spectroscopy  
 The determination of cellular uptake of cyanidin in differentiated H9c2 cells was initially 
attempted using its UV-Vis absorbance characteristics. 1.0104 H9c2 cells were seeded onto a 96-
well plate and allowed to differentiate for 7 days. Cells were then incubated in the differentiation 
medium with cyanidin (100 µM) at 37°C 5% CO2 for 10 min. The medium containing cyanidin 
was removed and the cells were washed twice with PBS to eliminate the extracellular cyanidin. 50 
µL ACN 0.1% FA was added to the wells to extract cyanidin. Cells were left to incubate for 30 
min at 4°C to complete the extraction. Using a Biotek reader, the absorbance was recorded at the 
predetermined λmax for cyanidin in ACN 0.1% FA (550 nm). Wells containing cells with no 
treatment were subjected to the same procedure and used as a control. In addition, the Biotek 
spectrometer UV-vis absorption spectra at a wavelength range of 200 – 800 nm were recorded 
after the completion of the incubation for cyanidin-treated and non-treated wells in the same 
treatment procedures.  
In other experiments, H9c2 cells were cultured in T75 flasks and allowed to differentiate for 
7 days. Cells were then trypsinized and centrifuged at 1200 RPM (4°C) to form a pellet. A final 
volume of 50 µL of cyanidin (100 µM) was incubated with the pellet for 10 min at 37°C. The 
pellet was then centrifuged and washed with PBS twice. The supernatant was then removed 
followed by the addition of ACN (0.1% FA) (50 µL). The pellet was subjected to vortexing and 
sonication in a bath sonicator for 5 min (kept at 4°C with ice) followed by incubation for 30 min 
(at 4°C) then by centrifugation in a benchtop microcentrifuge (1.0104 RPM at 4°C). The 
supernatant was taken out (60 µL) and placed in a well of a 96-well plate. The process was also 
performed for a control with no cyanidin addition. Measurement of the absorbance spectra (200-
800 nm) of samples was conducted using a Biotek spectrometer plate reader.   
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2.5.3. Determination of cyanidin uptake using its fluorescence characteristics 
Fluorescence measurement is a sensitive and specific technique to detect chemicals. Hence, 
we used the fluorescence of cyanidin to detect its presence intracellularly. ACN (0.1% FA) 
extraction solvent was used to determine the cellular uptake of cyanidin in differentiated H9c2 
cells using its fluorescence characteristics. 1.0104 H9c2 cells were seeded onto a 96-well plate 
and allowed to differentiate for 7 days. Cyanidin (100 µM) was added to each well and left to 
incubate for 10 min (at 37°C and 5% CO2). The incubation period was selected based on several 
considerations. Fiorani et al, 2010 was able to detect a similar flavonoid (quercetin) in Jurkat cells 
after just 10 min of incubation. In addition, degradative properties of cyanidin did not permit 
incubations for longer periods. The cells were washed twice with PBS followed by the addition of 
50 µL ACN 0.1% FA to each well to extract cyanidin. Cells were left to incubate for 30 min at 
4°C. Using a Biotek fluorometer, the fluorescence was measured for each well at excitation and 
emission wavelengths of 400 and 590 nm, respectively. These wavelengths were selected based 
on fluorescence intensity scans (Appendix 1). Control cells with no cyanidin addition were used 
as a control.  
2.5.4. Determination of cyanidin H9c2 cellular uptake using HPLC and fluorescence 
detection 
Another approach using HPLC and fluorescence detection was also employed to detect 
cyanidin in cellular extracts. This was conducted in two approaches. First, 10104 cells were 
cultured in a 6-well plate and left to differentiate. Cells were then incubated with cyanidin (100 
µM) in fresh differentiation medium for 10 min at 37°C. This was followed by the removal of the 
medium containing the cyanidin and washing the cells with PBS twice. 100 µL ACN (0.1%FA) 
was then added to each well and left to incubate for 30 min at 4°C. A cell scraper was then used 
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to ensure the collection of all cells. The cells and the supernatant were then collected into a 1.5 mL 
tube. The cells were centrifuged at 10103 RPM for 5 min (4°C). The cell lysate was then taken to 
HPLC. Different mobile phases (including methanol with 0.1% FA, ethanol with 0.1% FA) and a 
range of gradient (between 10 and 90%) were attempted to optimise the detection of the peaks. 
The same fluorescence excitation/emission (400/590 nm) wavelengths which gave positive results 
in fluorescence plate reader were used   
In another experimental approach, the differentiated H9c2 cells were trypsinized and 
centrifuged (1000 RPM for 5 min) to form a pellet. The pellet was then treated with cyanidin (100 
µM) in 50 µL differentiation medium for 10 min at 37°C and 5% CO2. The supernatant was 
removed, and cells were washed twice with PBS. 100 µL ACN (0.1% FA) was added to the pellet. 
The mixture was vortexed and sonicated in a bath sonicator for 5 min. The sample was centrifuged 
at 1.0104 RPM in a benchtop microcentrifuge at 4°C. 30 µL of the supernatant was then injected 
to the HPLC. The HPLC system used was from Agilent Technologies comprising an L-6200A 
pump and an L-4500 diode array detector. The analysis was performed using an Agilent Eclipse 
XDB-C18 column (150 × 4.6 mm, 5µm). All liquids used were HPLC grade. To determine the 
behaviour of cyanidin at physiological pH, HPLC was run at pH 7.4. Samples were diluted to a 
final concentration of 100 µM using PBS just before injection, and a mobile phase with no FA was 
used. The mobile solvents were water (A) and acetonitrile (B). The mobile phase started with 10% 
B from 0 to 2 min.  The percentage of B was at 70% from 2 to 20 min. Flow rate was 1 mL 
min−1 and temperature was 25°C. The presence of cyanidin flavylium ion was initially observed 
using the previously determined at λmax = 525 nm in acidic pH buffer solution (PBS pH 2.3). The 
λmax previously determined for PCA (λmax = 292 nm), PGA (λmax 315 nm) and cyanidin (λmax 
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585nm) at neutral pH were used. Therefore, the diode array detector was set to detect the 
absorbance at these wavelengths.  
2.5.5. Determination of cyanidin H9c2 cellular uptake using mass spectrometry 
Since MS tends to have high sensitivity, determining the small amounts of intracellular 
cyanidin is highly achievable. Therefore, we employed the technique to detect intracellular 
cyanidin flavylium ion and the degradation products.  To achieve this, H9c2 cells were cultured in 
a T75 flask and allowed to differentiate for 7 days (Section 4.2.1.). The cells were trypsinized and 
centrifuged to form a pellet. The supernatant was discarded, and the pellet was dispersed in a final 
50 µL differentiation medium with cyanidin (100 µM) and incubated for 10 min at 37°C. The 
sample was also mixed every 3-4 min during the incubation by manually inverting it twice.  The 
pellet was then centrifuged at 1.0104 RPM for 5 min (4°C) and washed twice with PBS. 50 µL 
ACN (0.1% FA) was added to the pellet to extract cyanidin. The pellet was subjected to vortexing 
and sonication for 5 min followed by centrifugation at 1.0104 RPM and 4°C. The lysate was then 
placed in a 1.5 mL tube and centrifuged at 1.0104 RPM for 5 min at 4°C followed by running the 
supernatant through a syringe filter (pore size 0.45 µm) to remove all debris. The sample was 
immediately taken for MS measurement. Wells containing cells with no cyanidin addition were 
subjected to the same extraction procedure and used as a control. The mass spectrometer was set 
to detect 307 Da (chalcone or hemiketal), 286 Da (quinoidal), 287 Da (flavylium ion) and 154 Da 
(PCA and/or PGA). MS parameters were set similar to those used in Section 4.5.3. 
 2.6. Statistical analyses 
All data were presented as means ± standard deviation (SD). Three different cell batches 
were used and for each batch, the experiment was conducted in quadruplicate. One way ANOVA 
followed by Tukey’s post-hoc test was used to determine the significance of the effects between 
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multiple groups using GraphPad Prism 5 software (San Diego, CA). Using the same software, T-
test was used to determine the significant effects between two groups. A p-value less than 0.05 
was considered significant. IC50 values were determined by plotting the change in cell survival 
percentage with the increase in concentration. Nonlinear regression analysis (with variable slope 




CHAPTER THREE: RESULTS 
 
3.1. CHARACTERISATION OF DOXORUBICIN’S EFFECTS ON DIFFERENTIATED 
H9C2 CELLS. 
3.1.1. Doxorubicin cytotoxicity in differentiated H9c2 cells  
Initial optimizations were conducted to determine the concentrations required to 
investigate doxorubicin’s effects on differentiated H9c2 cells. In differentiated H9c2 cells, the IC50 
of doxorubicin was 0.88 ± 0.24 µM after 24 h incubation (Figure 3.1), which is consistent with an 
IC50 value of 1 µM reported previously using differentiated H9c2 cells after 24 h of incubation 
(Branco et al, 2012).  
























Figure 3.1.: Cell survival as a function of doxorubicin concentration in differentiated H9c2 
cells after 24 h treatment. Differentiated H9c2 cells were treated with doxorubicin at 
concentrations of 0.1-10 µM and cytotoxicity determined by the SRB assay. Points represent mean 
± SD. The IC50 (0.883 + 0.242 µM) was determined by nonlinear regression analysis in GraphPad 
Prism. The experiment was repeated three times with 4 wells of cells per treatment.  
 
 Measurement of the IC50 was then followed with visually recording the effect of 
doxorubicin on H9c2 cellular viability over a period of time. Shown in Figure 3.2, 1 µM 
doxorubicin caused no apparent cell death (few floating round cells) when incubated with 
54 
 
differentiated H9c2 cells for 3 h or 6 h (Figure 3.2b&d) compared to control (Figure 3.2a&c). 
Extensive cell death was apparent after 12 and 24 h of incubation (Figure 3.2f&h).       
a.                                                                       b. 
                           
 
 
c.                                                                      d. 
         
 
e.                                                                       f. 









g.                                                                      h.  
        
 
Figure 3.2. Cell morphology of differentiated H9c2 cells in the absence or presence of 1 µM 
doxorubicin. Cells were allowed to differentiate for 7 days then treated: for 3 h (a) without and 
(b) with doxorubicin (1 µM); for 6 h (c, control; d, doxorubicin); for 12 h (e, control; f, 
doxorubicin); and for 24 h (g, control; h, doxorubicin). Images were taken using the ZOE 
microscope at an objective magnification of 20X. White arrows point to the dead cells.  
 The SRB assay was used to quantify the early and late cytotoxic effects of low and high 
doxorubicin concentrations on the differentiated H9c2 cells. Cell survival remained high after 3 
and 6 h of treatment with 1 µM doxorubicin (Figure 3.3). However, the percentage of cell survival 
decreased significantly by 14.5 and 59.0% at 12 and 24 h, respectively. A higher concentration of 
doxorubicin (5 µM) was attempted to capture the rapid effects on cell survival. However, no effect 
on cell survival after 3 and 6 h was apparent, but this concentration also caused significant 













































Figure 3.3: Survival of differentiated H9c2 cells with doxorubicin (1 or 5 µM) treatment for 
different exposure times. Differentiated cells were exposed to doxorubicin (1 or 5 µM) for 3, 6, 
12 and 24 h followed by the SRB assay. Values are presented in relation to the survival of control 
cells (absence of doxorubicin) incubated for the corresponding times. Three different cell batches 
were used and for each batch the experiment was conducted in quadruplicate. Bars represent means 
± SD. One way ANOVA with Tukey’s post-hoc analysis was used to determine the significance 
of treated groups compared to the control group. * Indicates significantly different from the control 
group at p < 0.05. 
 
 To investigate delayed effects of doxorubicin on differentiated H9c2 cells, doxorubicin (1 
µM) was added for 1, 3, 6, 12 and 24 h followed by its removal and addition of differentiation 
medium for 24 h. Under these experimental conditions, cell survival decreased only after 
incubation with 1 µM doxorubicin for 12 and 24 h (58.7 and 38.9% cell survival, respectively) 
(Figure 3.4). With 5 µM doxorubicin incubated for 1, 3 and 6 h followed by its removal and the 
addition of fresh differentiation medium for 24 h, the incubation periods of 3 and 6 h significantly 














































Figure 3.4: Survival of differentiated H9c2 cells after treatment with doxorubicin (1 or 5 µM) 
for different periods followed by incubation with fresh medium for 24 h. Percentage of cell 
survival was determined by the SRB assay after treatment with doxorubicin for different 
incubation periods. Values are presented in relation to the control. Three different cell batches 
were used and for each batch the experiment was conducted in quadruplicate. Bars represent means 
± SD. One way ANOVA with Tukey’s post-hoc analysis was used to determine the significance 
of the treated groups compared to the control group. * Indicates significant difference from the 
control group at p < 0.05.   
 
3.1.2 Doxorubicin effects on cellular and mitochondrial ROS production  
Different doxorubicin concentrations and incubation periods were investigated for effects 
on intracellular ROS and mitochondrial superoxide generation in differentiated H9c2 cells. At 1 
µM, doxorubicin significantly increased mitochondrial superoxide generation at 3 and 6 h of 
incubation by 49.69 and 89.07%, respectively, but had no effect at earlier times (Figure 3.5). A 
higher concentration (5 µM) caused a rapid (30 min) and significant increase in superoxide 

































































Figure 3.5:  Effect of doxorubicin on mitochondrial superoxide. Differentiated H9c2 cells were 
exposed to doxorubicin (1 or 5 µM) for different incubation periods, and rates of mitochondrial 
superoxide generation were measured using MitoSOX dye. Values are presented in relation to 
negative control. Three different cell batches were used and for each batch the experiment was 
conducted in quadruplicate. Bars represent means ± SD. One way ANOVA with Tukey’s post-hoc 
analysis was used to determine the significance of the treated groups compared to the control 
group. * Indicates a significant difference between the doxorubicin treated group and the control 
group.  
 
In measurements of the effects of doxorubicin on intracellular ROS, no significant effects 
were observed after 30 and 60 min exposure using a low (1 µM) concentration (Figure 3.6). 
Incubation with 1 µM doxorubicin for 3, 6, 12 and 24 h however, produced significant increases 
in intracellular ROS generation by 22.7, 74.0, 75.4 and 57.9%, respectively (Figure 3.6). The 
incubation with higher concentrations of doxorubicin (5 and 20 µM) for 30 or 60 min also caused 
























































   
Figure 3.6: Effects of doxorubicin (1, 5 and 20 µM) incubation for different times on 
intracellular ROS generation. Differentiated H9c2 cells were incubated with doxorubicin (1, 5 
or 20 µM) for different incubation periods followed by measurement of intracellular ROS 
generation using DCFH-DA dye. Values are presented in relation to the corresponding control. 
Three different cell batches were used and for each batch the experiment was conducted in 
quadruplicate. Bars represent means ± SD. One way ANOVA with Tukey’s post-hoc analysis was 
used to determine significant differences from control groups. * Indicates a significant difference 
between the doxorubicin treated group and the control group.  
   
3.1.3. Doxorubicin effects on mitochondrial function 
The MTT assay was used to detect changes in the metabolic activity produced by 
doxorubicin in differentiated H9c2 cells. Doxorubicin (5 µM) treatment for 6 h significantly 
decreased MTT reductase enzyme activity by 34.1% (Figure 3.7). Incubation periods of 1 and 3 




















































Figure 3.7: Effect of doxorubicin for different time periods on metabolic activity. 
Differentiated H9c2 cells were exposed to doxorubicin (5 µM) for 1, 3, or 6 h followed by the 
addition of MTT to detect metabolic activity. Values are presented in relation to the control 
(absence of doxorubicin). Three different cell batches were used and for each batch the experiment 
was conducted in quadruplicate. Bars represent means ± SD. One way ANOVA with Tukey’s post-
hoc analysis was used to determine the significance of the treated groups compared to the control 
group. * Indicates a significant difference between the doxorubicin treated group and the 
corresponding control group at that time.  
 
 Measurements of MMP were used to investigate the early (direct) and late (apoptosis-
mediated) effects of doxorubicin on the MMP in differentiated H9c2 cells. No significant change 
in the MMP was observed after 3 or 6 h of 1 µM doxorubicin incubation (Figure 3.8). However, 
a significant decrease in the MMP was observed after a more prolonged exposure (12 h) (Figure 
3.8). A higher concentration (5 µM) of doxorubicin was unable to decrease the MMP in a short 
(30 min) incubation period, but decreased MMP by 29.3 and 47.9% after 3 and 6 h, respectively 
(Figure 3.8). Notably, 5 µM doxorubicin did not decrease cellular protein (SRB assay) at these 







































Figure 3.8: Effect of doxorubicin for different time periods on MMP. Differentiated H9c2 cells 
were exposed to doxorubicin (1 or 5 µM) for 0.5, 3, 6 and 12 h followed by the addition of TMRE 
probe for MMP measurement. Due to a decrease in cell number at 12 h of doxorubicin exposure 
(Fig. 5.3), the fluorescence intensities were normalized to the cell density (from SRB 
fluorescence). Values are presented in relation to the control (absence of doxorubicin). Three 
different cell batches were used and for each batch the experiment was conducted in quadruplicate. 
Bars represent means ± SD. One way ANOVA with Tukey’s post-hoc analysis was used to 
determine significant difference between the doxorubicin and control group. * Indicates a 
significant difference between the doxorubicin treated group and the corresponding control group 




3.2. PROTECTION BY DIFFERENT FLAVONOIDS AGAINST DOXORUBICIN-
INDUCED CYTOTOXICITY, ROS GENERATION AND MITOCHONDRIAL 
DYSFUNCTION IN DIFFERENTIATED H9C2 CELLS 
3.2.1. Protection against doxorubicin cytotoxicity.  
In order to compare with the literature, the cytoprotective ability of cyanidin against 
doxorubicin was initially measured using undifferentiated H9c2 cells (Choi et al, 2007). A 
significant increase in cell survival (by 26.0 and 46.92%, respectively) was noticed when 
doxorubicin (1 µM) was incubated for a period of time followed by cyanidin (50 and 100 µM) 
treatment (Figure 3.9). Treatment of differentiated H9c2 cells with doxorubicin (1 µM) and 
cyanidin (50 and 100 µM) following the same pattern significantly increased cell survival by 66.6 

















































Figure 3.9: Cell survival of undifferentiated and differentiated H9c2 cells when treated with 
doxorubicin followed by cyanidin. Doxorubicin (1 µM) was added to undifferentiated and 
differentiated H9c2 cells and incubated for 24 h followed by its removal and addition of fresh 
medium containing cyanidin (10, 50 or 100 µM) and incubation for 24 h. Cell survival was then 
determined by the SRB assay. Values are presented in relation to the survival of control cells in 
the absence of treatments. Bars represent means ± SD. One way ANOVA with Tukey’s post-hoc 
analysis was used to determine the significance of the difference between cyanidin treated groups 
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and the doxorubicin treated group. * Indicates a significant difference from the doxorubicin group 
at p < 0.05. Doxorubicin was significantly different from the control group. Doxo: doxorubicin.  
 
Since proactive protection is more desirable than post-protection, cyanidin (100 µM) and 
doxorubicin (0.25, 0.50 or 1.00 µM) were co-administered to the differentiated H9c2 cells for 24 
h. Under these experimental conditions, cyanidin failed to show significant protective ability 
(Figure 3.10a). In addition, to ensure its presence in the cells, 1 h pre-incubation of cyanidin (100 
µM) with the cells before the addition of doxorubicin (1 µM) was conducted. The result showed a 
lack of protection in this experimental condition (Figure 3.10b). In addition, no significant 
protection from doxorubicin (1 µM) was observed with multiple additions of cyanidin (10 µM 
every 8 h) (Figure 3.10b).  
a.                                                                       b. 














































































Figure 3.10: Cell survival of differentiated H9c2 cells when treated with doxorubicin and 
cyanidin together for 24 h. Differentiated H9c2 cells were treated with cyanidin and doxorubicin 
in different doses and patterns, and cell survival after 24 h was determined by the SRB assay. a) 
Cyanidin (100 µM) and doxorubicin (0.25, 0.5 or 1 µM) were added to the differentiated H9c2 
cells together and incubated for 24 h. b) For the single treatment, cyanidin (100 µM) was pre+co-
incubated (Pre+Co) with differentiated cells for 1 hr followed by the addition of doxorubicin (1 or 
5 µM) and their co-incubation for 24 h. For the multi-treatments (Multi), cyanidin (10 µM) was 
initially added together with doxorubicin (1 or 5 µM), and then 10 µM cyanidin was added every 
8 h until up to 24 h (3 additions). Values are presented in relation to the survival of control cells in 
the absence of treatments. Three different cell batches were used and for each batch the experiment 
was conducted in quadruplicate. Bars represent means ± SD. T-test  was used to determine the 
significance of the effects between cyanidin treatment and the corresponding doxorubicin group. 
Doxorubicin was significantly different from the control group in all cases. Doxo: doxorubicin.  
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Using differentiated H9c2 cells, the protective effect of cyanidin was compared with other 
flavonoids (namely C3G, quercetin, and catechin) when applied after doxorubicin exposure (post-
treatment pattern). Significant increases in cell survival were observed with cyanidin at 50 and 100 
µM, quercetin at 100 µM and C3G at 100 µM (Figure 3.11a). The protective effect of cyanidin 
was also compared to that of its metabolites (PCA and PGA). Significant increases in cell survival 
were observed with cyanidin and the combination of its two degradation products in doxorubicin 
exposed differentiated H9c2 cells (Figure 3.11b). However, cyanidin (50 and 100 µM) gave 13.1 
and 19.9% greater survival than PCA+PGA (50 and 100 µM of each), respectively, with increased 
cell survival at 100 µM being significantly different.    



















































































































































































Figure 3.11: Cell survival of differentiated H9c2 cells when treated with doxorubicin 
followed by a flavonoid. A comparison between the protection ability of a) different flavonoids 
(50 or 100 µM) or b) cyanidin and PGA+PCA against doxorubicin’s cytotoxicity. The PCA+PGA 
conditions received the indicated concentration of each compound. Cell survival was determined 
by the SRB assay. Values are presented in relation to the control survival. Bars represent means ± 
SD. One way ANOVA with Tukey’s post-hoc analysis was used to determine the significance of 
the difference between flavonoid treated groups and the doxorubicin treated group. * Indicates a 
significant difference from the doxorubicin group at p < 0.05. Doxorubicin was significantly 
different from the control group. + indicates a significant difference from the “PCA&PGA 
100µM” group.  Doxo: doxorubicin, Cya: cyanidin, Quer: quercetin, Cat: catechin, C3G: cyanidin-
3-glucoside.    
 
Differentiated H9c2 cells were also treated with doxorubicin and cyanidin for a period of 
time followed by a 24 h drug free period. Cyanidin significantly increased cell survival by 15.1 
and 21.7% at 12 h and 24 h, respectively (Figure 3.12a). This was followed by the comparison of 
the cytoprotective effects of different flavonoids and cyanidin utilizing the same treatment pattern. 
All four flavonoids were able to significantly protect against loss of cell viability (Figure 3.12b), 
with cyanidin and quercetin giving the strongest survival (an increase by 34.0%). The protective 
effects of cyanidin were also compared to that of its metabolites (PCA and PGA) using the same 
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treatment pattern. Both cyanidin and its two degradation products significantly enhanced cell 
survival following exposure to doxorubicin (Figure 3.12c). However, cyanidin (50 or 100 µM) 
significantly increased cell survival by 16.0% or 20.2% over PCA&PGA (50 or 100 µM), 
respectively. 






























































































































































Figure 3.12: Delayed cytoprotective effects of flavonoids when added together with 
doxorubicin (1 µM) and replaced by fresh medium for another 24 h. Doxorubicin was co-
treated with a) Cyanidin (100 µM) 12 or 24 h, b) Flavonoid (100 µM) for 24 h, c) PCA&PGA or 
cyanidin for 24 h, followed by a drug free 24 h period. The treatments were followed by a drug 
free 24h. Cell survival was then determined by the SRB assay. The PCA&PGA were added at 50 
or 100 µM each. Cell survival was determined relative to control. Three different cell batches were 
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used and for each batch the experiment was conducted in quadruplicate. Bars represent means ± 
SD. One way ANOVA with Tukey’s post-hoc analysis was used to determine the significance of 
the effects between groups (p value < 0.5).  * Indicates a significant difference from the 
doxorubicin alone group. + indicates a significant difference between the cytoprotection by 
cyanidin (100 µM) and that for PCA&PGA (100 µM). # indicates a significant difference between 
the cytoprotection by cyanidin (50 µM) and that for PCA&PGA (50 µM).  Doxorubicin was 
significantly different from the control (absence of doxorubicin) group in all panels. Doxo: 
doxorubicin, Cya: cyanidin, Quer: quercetin, Cat: catechin, C3G: cyanidin-3-glucoside.  
 
To capture the protective effect of the flavonoids at early stages, short incubations were 
performed with a high concentration of doxorubicin. All flavonoids were able to significantly 
protect the cells from doxorubicin (5 µM) when incubated together for 6 h followed by their 
replacement with fresh medium for 24 h (Figure 3.13). However, when the treatments lasted 1 h 











































Figure 3.13: Delayed cytoprotective effects of flavonoids when added together with 
doxorubicin (1 µM) and replaced by fresh medium for another 24 h. Flavonoid (100 µM) co-
treatments for 1, 3 or 6 h, followed by their removal and the addition of fresh medium for 24 h. 
Values are presented in relation to the control survival. Three different cell batches were used and 
for each batch the experiment was conducted in quadruplicate. Bars represent means ± SD 
expressed as a percentage of control cells. One way ANOVA with Tukey’s post-hoc analysis was 
used to determine the significance of the effects between groups (p value < 0.5).  For each time 
point, * indicates a significant difference between doxorubicin alone group and the flavonoid 
treated group. Doxorubicin was significantly different from the control (absence of doxorubicin) 
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group in all panels. Doxo: doxorubicin, Cya: cyanidin, Quer: quercetin, Cat: catechin, C3G: 
cyanidin-3-glucoside.   
 
 
3.2.2. Protection against doxorubicin–induced mitochondrial and cellular ROS 
These experiments were conducted to explore the protective effect of flavonoids on 
doxorubicin-affected mitochondrial superoxide and intracellular ROS generation in differentiated 
H9c2 cells following different concentrations and incubation periods. Cyanidin and C3G 
significantly decreased mitochondrial superoxide generation after 3 h by 33 and 23%, respectively, 
compared to doxorubicin alone, while quercetin and catechin had no significant effect (Figure 
3.14a). After 6 h, all of the flavonoids produced significant decreases (by 33.3, 22.1, 19.2 and 
19.8% with cyanidin, quercetin, catechin and C3G, respectively), compared to doxorubicin alone 
(Figure 3.14a). With 12 h incubation, only cyanidin showed a significant decrease in 
mitochondrial superoxide generation (by 19%) compared to doxorubicin alone (Figure 3.14a). 
When the ability of the flavonoids to decrease the acute (30 min) doxorubicin (5 µM)-induced 
mitochondrial superoxide generation was measured, a significant decrease (by 55.8%) with 








































































































































Figure 3.14: Effect of different flavonoids on mitochondrial superoxide generation induced 
by doxorubicin (1 or 5 µM). Differentiated H9c2 cells were incubated with doxorubicin a) 1 µM 
for 3, 6 or 12 h or b) 5 µM for 0.5 h with or without a flavonoid (100 µM). MitoSOX was used to 
measure the level of mitochondrial superoxide generation. The values were then normalised to 
SRB values. Values are presented in relation to the control cells. Three different cell batches were 
used and for each batch, the experiment was conducted in quadruplicate. Bars represent means ± 
SD. One-way ANOVA with Tukey post-hoc analysis was used to determine the significance of 
the effects between groups. * Indicates a significant difference from the doxorubicin-treated group 
(p < 0.05). Doxorubicin was significantly different from the control group. Doxo: doxorubicin, 
Cya: cyanidin, Quer: quercetin, Cat: catechin, C3G: cyanidin-3-glucoside.  
 
Since measurements of intracellular ROS generation did not show significant increases by 
doxorubicin at early time points (Figure 3.15), the effects of flavonoids on doxorubicin-induced 
intracellular ROS were determined after 6 and 12 h. Only cyanidin caused a significant reduction 
in intracellular ROS generation by 35.0% when treated together with doxorubicin for 6 h (Figure 
3.15). When the incubation lasted 12 h, a slight, but significant decrease in doxorubicin-induced 































































   
Figure 3.15: Effect of different flavonoids on intracellular ROS generation induced by 
doxorubicin (1 µM). Differentiated H9c2 cells were incubated with doxorubicin (1 µM) with or 
without a flavonoid (100 µM) for 6 or 12 h. Intracellular ROS generation was then measured using 
DCFH-DA. The results for intracellular ROS were normalized to the measured adherent cell 
density. Values are presented in relation to the control. Three different cell batches were used and 
for each batch, the experiment was conducted in quadruplicate. Bars represent means ± SD. One-
way ANOVA with Tukey post-hoc analysis was used to determine the significance of the effects 
between groups. * Indicates a significant difference from the doxorubicin-treated group (p < 0.05). 
Doxorubicin was significantly different from the control group. Doxo: doxorubicin, Cya: cyanidin, 
Quer: quercetin, Cat: catechin, C3G: cyanidin-3-glucoside.  
 
3.2.3 Protection by flavonoids against mitochondrial dysfunction and morphological 
changes induced by doxorubicin 
Measurements of metabolic activity and MMP using MTT and TRME dyes, respectively, 
were employed to understand the ability of the flavonoids to protect against the effect of 
doxorubicin on metabolic functions. With the MTT assay, all flavonoids except C3G were able to 
increase mitochondrial function by 26.83, 18.99, and 18.5% for cyanidin, quercetin, and catechin, 
respectively, compared to doxorubicin (5 µM) alone when incubated together (Figure 3.16a). In 
measurements of MMP in cells treated with doxorubicin (1 µM) with or without a flavonoid (100 






















































































































Figure 3.16: Effects of flavonoids and doxorubicin on metabolic functions. a) Doxorubicin (5 
µM) with or without a flavonoid (100 µM) was incubated with differentiated H9c2 cells for 6 h. 
This was followed by the measurement of metabolic function using the MTT assay. b) 
Differentiated H9c2 cells were incubated with doxorubicin (1 µM) with or without a flavonoid for 
12 h. MMP levels were then determined using TRME dye. Values are presented in relation to 
control cells in the absence of doxorubicin. Three different cell batches were used and for each 
batch, the experiment was conducted in quadruplicate. Bars represent means ± SD. One-way 
ANOVA with Tukey post-hoc analysis was used to determine the significance of the effects 
between groups. * Indicates a significant difference between the doxorubicin-treated group and 
the flavonoid-treated group (p value < 0.05). Doxorubicin was significantly different from the 
control group. Doxo: doxorubicin, Cya: cyanidin, Quer: quercetin, Cat: catechin, C3G: cyanidin-
3-glucoside.      
            
We also assessed the ability of cyanidin to protect against changes in mitochondrial 
morphology caused by doxorubicin using electron microscopy. Doxorubicin decreased the number 
of mitochondrial cristae (Figure 3.17b) compared to control cells (Figure 3.17a). Following 
treatment with cyanidin fewer changes in mitochondrial morphological features were observed 
with exposure to doxorubicin when given in either “post-treatment” or “co-treatment with delayed 
assessment” patterns (Figure 3.17c&d). However, all cyanidin-treated cells retained some 






















Figure 3.17: Mitochondrial morphology changes detected by EM. Differentiated H9c2 cells 
were incubated in differentiation medium with a) no treatment for 48 h (control) (an arrow pointing 
at a mitochondrion in this cell has a complete cristae indicating its healthy structure) b) 
doxorubicin (1 µM) for 24 h, followed drug free period (24 h) (an arrow shows a mitochondrion 
with disrupted cristae, and the image shows other disrupted mitochondria and intracellular 
damage) c) doxorubicin (1 µM) for 24 h followed by its removal and the addition of cyanidin (100 
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µM) for 24 h (The arrow shows a mitochondrion with partially restored cristae and the image 
shows other mitochondria in a similar condition) d) doxorubicin (1 µM) together with cyanidin 
(100 µM) for 24 h followed by a drug free period for 24 h (the arrows show mitochondria with 



























3.3. DETECTION OF INTRACELLULAR CYANIDIN  
3.3.1. Absorptivity, stability and fluorescence characteristics of cyanidin in different 
solvents.   
Initially, the stability and the UV-vis absorbance and fluorescence characteristics of 
cyanidin were identified in different solvents. Cyanidin’s behaviour in these solvents determined 
the suitable extraction solvent for intracellular uptake measurements.   
Absorptivity of cyanidin  
The objective of this experiment was to determine the absorptivity of cyanidin when 
dissolved in different extraction solvents (PBS with 0.1% tween-20 and 0.1% FA, ACN with 0.1% 
FA, methanol with 0.1% FA, DMSO). The absorptivity at 550 nm was determined to be similar 
and ranged from 0.0016 µM-1 (PBS 0.1% tween-20 and 0.1% FA) to 0.0019 µM-1 (ACN 0.1% 
FA), Figure 3.18.  
 
Figure 3.18: Absorptivity at 550 nm of cyanidin in different solvents. Cyanidin was dissolved 
in ACN (0.1% FA), methanol (0.1% FA), PBS (0.1% FA and 0.1% tween-20) or DMSO at 
different concentrations. The absorptivity was calculated as the slope of the line plotted from the 
























Stability of cyanidin  
The purpose of this evaluation was to determine the stability of cyanidin in different 
extraction solvents. Cyanidin was found to be highly stable in DMSO, and in ACN or methanol, 
each supplemented with 0.1% FA. Only 8, 10 and 12% decreases in absorbance at 550 nm after 
60 min were observed at room temperature when cyanidin was dissolved in DMSO, ACN 0.1%FA 
and methanol 0.1% FA, respectively. However, a 27% decrease in absorbance after 60 min was 
observed when cyanidin was dissolved in PBS supplemented with 0.1% tween-20 and 0.1% FA.  
Fluorescence characteristics of cyanidin 
After measuring its fluorescence at different excitation and emission wavelengths, cyanidin 
(100 µM) had a maximum 7.30 fold increase in fluorescence intensity (Ex: 400 Em: 590) compared 
to the blank when dissolved in DMSO. Cyanidin (100 µM) had 3.80, 3.84 and 2.60 fold increases 
in fluorescence (Ex: 400 Em: 590) (Appendix A) over the solvents alone when dissolved in PBS 
(0.1% FA and 0.5% tween-20), ACN (0.1% FA) and methanol (0.1% FA).  
Finally, the solvents which resulted in the highest cyanidin fluorescence intensity, the 
highest absorptivity and the highest stability was selected for cyanidin extraction measurements. 
Therefore, DMSO or ACN (0.1% FA) were used as extraction solvents to determine the cellular 
uptake of cyanidin in differentiated H9c2 cells using its fluorescence characteristics. 
3.3.2. Determination of intracellular cyanidin using UV-vis and fluorescence spectroscopy, 
HPLC and MS  
UV-vis spectroscopy 
The detection of intracellular uptake of cyanidin in differentiated H9c2 cells seeded in a 
96-well plate was initially attempted using UV-vis absorbance after incubation with 100 µM 
cyanidin for 10 min. Despite the high concentration of cyanidin in the medium that was retained 
throughout the 10 min experiment time (as shown in degradation experiments), no UV-vis 
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absorbance was detected in extracts from cyanidin-treated cells. That is, no difference in 
absorbance was recorded between the cyanidin treated and the control cells when extracted with 
DMSO or ACN (0.1% FA). In addition, to verify if any change to the λmax might have occurred 
after the incubation with the cells, full absorbance scans were conducted on the cell lysate. No 
difference in absorbance spectrum was observed between the cyanidin-treated and control cells 
when extracted by ACN (0.1% FA).  In addition, when cyanidin was incubated with pelleted H9c2 
cells followed by the extraction with ACN (0.1% FA) and the measurement of UV-vis spectrum 
of the extract, no difference in the absorbance spectrum was detected compared to the control.  
Fluorescence spectroscopy 
Using DMSO as the extraction solvent, cyanidin was not detected in cyanidin treated-H9c2 
cells (results not shown). We also utilized the fluorescence characteristics of cyanidin in ACN 
(0.1% FA) to detect its presence intracellularly. Using excitation and emission wavelengths of  400 
nm and 590 nm, respectively, a difference in fluorescence intensity between the cyanidin-treated 
and control cells was observed (Figure 3.19b). The standard curve obtained from plotting the 
concentration vs fluorescence intensity (Figure 3.19a) was employed to determine cyanidin’s 
concentration in extraction solvent after treatment of cells. The concentration was found to be 29.9 
µM in 50 µL of ACN (0.1% FA) after extraction (giving an amount of 0.430 µg). Knowing that 
the concentration of cyanidin added to the cells was 100 µM in 100 µL, the original amount of 
cyanidin is equal to 2.87 µg. This implies that 14.97% of the cyanidin was taken up by the cells. 
Importantly, incubating the cells with the cyanidin degradation products PCA and PGA followed 
by subjecting them to the same conditions showed no difference in fluorescence compared to 













































Figure 3.19: Intracellular cyanidin detection using fluorescence and ACN (0.1% FA). 
Determination of intracellular cyanidin was conducted using fluorescence (Ex: 400 and Em: 590) 
detection after extraction with ACN (0.1% FA). Fluorescence intensity of a) ACN (0.1% FA) cell 
extracts spiked with different concentrations of cyanidin to form a standard curve for cyanidin and 
b) lysate of differentiated H9c2 cells incubated with cyanidin (100 µM) in a 96 well plate for 10 
min (37°C, 5% CO2), followed by washing with PBS and extraction with ACN 0.1% FA. 
Fluorescence intensity was measured at (Ex: 400 and Em: 590). * Indicated a significant difference 
between the detected fluorescence intensity in cyanidin treated cells and the control. Cya: cyanidin. 
 
HPLC detection 
Using the two HPLC approaches (with UV-vis or fluorescence detection) the method failed 
to detect cyanidin or any of its products after cellular extraction with ACN (0.1% FA) (results not 
shown). 
MS detection  
The detection of the intracellular amounts of cyanidin, after incubation with pelleted cells 
for 10 min, was attempted using MS. MS failed to detect cyanidin in the samples extracted with 
ACN (0.1% FA). Results showed that the extract from control and treated cells had similar peaks 



























PGA, flavylium ion, hemiketal, or chalcone after treatment of differentiated H9c2 cells with 
cyanidin and their extraction with ACN (0.1% FA). 
3.4. EVALUATION OF CYANIDIN AND QUERCETIN AS ANTI-CANCER 
POTENTIATORS OR INHIBITORS ON HEPG2 AND K562 CELLS IN THE PRESENCE 
AND ABSENCE OF DOXORUBICIN 
3.4.1. Cytotoxicity effects of cyanidin and quercetin in HepG2 and K562 cells in the presence 
and absence of doxorubicin  
The IC50 of doxorubicin was initially calculated for HepG2 and K562 cells using the SRB 
assay. The IC50 was 1.59 + 0.22 and 1.17 + 0.46 µM with HepG2 and K562 cells, respectively 
(Figure 3.20).   
a.                                                                        b.  





















































Figure 3.20: Dose-response curve for doxorubicin in HepG2 and K562 cells. a) HepG2 and b) 
K562 cells were incubated with doxorubicin at different concentrations for 72 h, and the SRB 
assay was used to determine cell density. Three different cell batches were used and for each batch 
the experiment was conducted in quadruplicate. Points represent means ± SD. Doxo: doxorubicin  
The effect of cyanidin and quercetin on doxorubicin cytotoxicity to HepG2 and K562 cells 
was then evaluated. Cyanidin showed no effect on doxorubicin toxicity with either treatment 
protocol or cell line (Figure 3.21a&b). In HepG2 cells, quercetin produced no significant effect 
on cell survival when it was added only once with doxorubicin (Figure 3.21a). In K562 cells 
however, 100 µM quercetin produced a significant 7% decrease in survival compared to 
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doxorubicin alone (Figure 3.21b). With multiple additions, quercetin (100 µM each) significantly 
decreased HepG2 cell survival by 53.3%. In K562 cells, the multiple additions of 50 or 100 µM 
quercetin caused a significant decrease in cell survival by 23.6 or 34.6%, respectively (Figure 
3.21a&b).  




























































































Figure 3.21: Effect of cyanidin and quercetin on the survival of HepG2 or K562 cells when 
treated with doxorubicin.  Doxorubicin with or without the flavonoids was added to a) HepG2 
or b) K562 cells. Cyanidin or quercetin (50 µM or 100 µM) were added either once (single 
treatment) or every 24 h for 72 h (total of 3 times addition) (multiple treatments). A concentration 
of 1 or 1.5 µM for doxorubicin for HepG2 or K562 cells. The SRB assay was used to quantify the 
cell survival percentage. Values are presented in relation to the control survival. Three different 
cell batches were used and for each batch the experiment was conducted in quadruplicate. One 
way ANOVA was used to determine the significance of the effects between groups using 
GraphPad Prizm. * Indicates a significant difference between the treated groups and the 
doxorubicin group. Doxorubicin was significantly different from the control group. Doxo: 




The cytotoxicity of cyanidin and quercetin against HepG2 or K562 cells were also 
evaluated when added without doxorubicin. Cyanidin showed no effect on cell survival in either 
cell line despite its addition every 24 h (for 72 h), (Figure 3.22). Quercetin, added at 100 µM 
initially and every 24 h over 72 h, significantly reduced cell survival by 37.7% in HepG2 cells, 



































Figure 3.22: Effects of cyanidin and quercetin alone on HepG2 and K562 cell survival. 
Cyanidin or quercetin (100 µM additions) were added to HepG2 or K562 cells initially and every 
24 h for 72 h (total of three additions). The SRB assay was employed to determine the cell survival. 
Values are presented in relation to the control survival. Three different cell batches were used and 
for each batch the experiment was conducted in quadruplicate. T-test was used to determine the 
significance of the effect between the treatment and control group using GraphPad Prism. * 
Indicates a significant difference between the treated group and the control group. Doxo: 
doxorubicin, Cya: cyanidin, Quer: quercetin.   
 
3.4.2. Mitochondrial effects of cyanidin and quercetin in HepG2 and K562 cells in the 
presence and absence of doxorubicin  
Quercetin or cyanidin were co-treated with doxorubicin to evaluate their possible 
potentiating or inhibitory activity on mitochondrial energy metabolism. While doxorubicin was 
added only once, the flavonoids were added initially and every 24 h for 72 h (total of three 
additions). Cyanidin showed no effect on doxorubicin toxicity in this experimental condition in 
either cell line (Figure 3.23a&b). With HepG2 cells, the co-treatment of doxorubicin and querctin 
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(100 µM  3) caused a significant reduction in MTT by 67.4% (Figure 3.23a). With K562 cells, 
quercetin together with doxorubicin caused significant decreases in MTT (normalised to SRB-
determined cellular protein) (by 12.7 and 43.8%) with 50 and 100 µM additions of quercetin, 
respectively, compared to doxorubicin alone (Figure 3.23b).  









































































































































































































Figure 3.23: Effect of flavonoids on doxorubicin-induced changes in mitochondrial energy 
metabolism in HepG2 and K562 cells. Doxorubicin (1.5 µM for HepG2 and 1.0 µM for K562 
cells) with or without one of the flavonoids (50 or 100 µM) was added to a) HepG2 or b) K562 
cells. However, while doxorubicin was added only once initially, flavonoids (50 or 100 µM) were 
added initially and every 24 h for 72 h (3 total additions). MTT dye was then employed to quantify 
the metabolic activity. Values are presented in relation to the control MTT reduction values 
normalized to cellular protein determined by the SRB assay done in the same wells. Three different 
cell batches were used and for each batch the experiment was conducted in quadruplicate. One-
way ANOVA with Tukey’s post-hoc test was used to determine the significance of the effects 
between groups using GraphPad Prism. * Indicates a significant difference between the flavonoid 
treated group and the doxorubicin group. Doxorubicin was significantly different from the control 
group. Doxo: doxorubicin, Cya: cyanidin, Quer: quercetin. 
 
 The MMP assay was also used to explore the combined effects of cyanidin or quercetin 
with doxorubicin on mitochondrial function in HepG2 and K562 cells. In HepG2 cells treatment 
with doxorubicin (1 µM) without a flavonoid for 24 h significantly lowered MMP (Figure 3.24a). 
Cyanidin showed no effect, but quercetin significantly decreased MMP by 30.4% compared to 
HepG2 cells treated with doxorubicin alone. With K562 cells, cyanidin again had no effect but 
83 
 
quercetin caused a significant decrease (by 24.1%) after 12 h of treatment compared to doxorubicin 
(1.5 µM) alone (Figure 3.24b). As determined by the SRB assay, the density of cellular protein 
did not change after 24 h incubation using both cell lines (data not shown).  
     a.                                                                          b.  










































































Figure 3.24: Effect of flavonoids on doxorubicin-induced changes to mitochondrial 
membrane potential (MMP) in HepG2 and K562 cells. Doxorubicin (1 µM) with or without 
one of the flavonoids (100 µM) was added to a) HepG2 or b) K562 cells, and incubated for 24 h 
or 12 h, respectively. MMP was then measured using TMRE dye. No effects on SRB were seen at 
these incubation times, so normalization to cell density was not needed. Three different cell 
batches were used and for each batch, the experiment was conducted in quadruplicate. Bars 
represent means ± SD. One-way ANOVA with Tukey’s post-hoc analysis was used to determine 
the significance of the effects between groups. Doxorubicin was significantly different from the 
control. * Indicates a significant difference from the doxorubicin-treated group (p < 0.05). Doxo: 
doxorubicin, Cya: cyanidin, Quer: quercetin.             
 
3.4.3. Effects of cyanidin and quercetin on doxorubicin-induced intracellular ROS 
generation in HepG2 and K562 cells 
Assessments of intracellular ROS generation were conducted to understand the possible 
mechanisms involved in any inhibitory or potentiating effects of the flavonoids with doxorubicin. 
With HepG2 cells, quercetin significantly enhanced the effect of doxorubicin on intracellular ROS 
generation, while cyanidin failed to show such capability (Figure 3.25). With K562 cells, both 
flavonoids failed to cause any significant increase in ROS compared to doxorubicin alone (Figure 
3.25).    
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     a.                                                                        b. 




































































































Figure 5.25: Effect of cyanidin and quercetin on doxorubicin-induced reactive oxygen species 
(ROS) in HepG2 and K562 cells Doxorubicin (1 µM) with or without one of the flavonoids (100 
µM) was added to a) HepG2 or b) K562 cells and incubated for 24 h. Intracellular ROS generation 
was then measured using DCFH-DA dye. Values are presented in relation to the control. Three 
different cell batches were used and for each batch, the experiment was conducted in quadruplicate. 
Bars represent means ± SD. One-way ANOVA with Tukey’s post-hoc analysis was used to 
determine the significance of the effects between groups. * Indicates a significant difference from 
the doxorubicin-treated group (p < 0.05). Doxorubicin was significantly different from the control 
group. Doxo: doxorubicin, Cya: cyanidin, Quer: quercetin.  
 
3.4.4. Effects of cyanidin and quercetin on the ability of doxorubicin to cause DNA 
fragmentation in HepG2 and K562 cells 
 The COMET assay was conducted to evaluate the effect of cyanidin and quercetin on 
doxorubicin-induced DNA damage in HepG2 and K562 cells. The images in Figure 5.26 show no 
COMET tail in the control HepG2 (panel a) or K652 (panel e) cells, but COMET tails are apparent 
in all of the conditions with doxorubicin. The quantified results of percent of DNA in the tail are 
shown in Figure 5.26. With HepG2 cells, exposure to doxorubicin (1 µM) for 72 h significantly 
increased the amount of fragmented DNA to 33.8% (Figure 5.27). Quercetin significantly 
increased the fragmented DNA by 27.7% over doxorubicin alone. Cyanidin had no effect on DNA 
fragmentation caused by doxorubicin.  
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In K562 cells, doxorubicin for 72 h caused an increase in DNA fragmentation to 26.1±7.4% 
(Figure 3.25). Cyanidin had no significant effect on DNA fragmentation compared to doxorubicin 
alone, however, quercetin increased the fragmentation by 46.4%.  
a.                                                                         b.                                                                                
     
 
c.                                                                         d.  
         













e.                                                                         f.                                                                            
     
 
g.                                                                         h.     
         
     
Figure 3.26: Effects of cyanidin and quercetin on doxorubicin-induced DNA fragmentation 
in HepG2 and K562 cells. HepG2 cells were incubated for 72 h with a) no additions, b) 
doxorubicin (1 µM), c) doxorubicin (1 µM) and cyanidin (100 µM), or d) doxorubicin (1 µM) and 
quercetin (100 µM), followed by the COMET assay. K562 cells were treated for 72 h with e) no 
additions, f) doxorubicin (1 µM) g) doxorubicin (1 µM) and cyanidin (100 µM), or h) doxorubicin 
(1.5 µM) and quercetin (100 µM), followed by the COMET assay. Three different cell batches 















































































Figure 3.27:  Effect of doxorubicin on DNA fragmentation with or without a flavonoid in 
HepG2 and K562 cells. a) HepG2 or b) K562 cells were exposed to doxorubicin with or without 
cyanidin or quercetin followed by COMET assay. Values are presented in relation to the control. 
Three different cell batches were used and for each batch, the experiment was conducted in 
quadruplicate. Bars represent mean ± SD. One-way ANOVA with Tukey’s post-hoc analysis was 
used to determine the significance of the effects between groups. * Indicates a significant 
difference from the doxorubicin-treated group (p < 0.05). Doxorubicin was significantly different 




3.5. DEGRADATION OF CYANIDIN  
3.5.1 Comparison of rates of disappearance in different media using UV-vis measurements  
Cyanidin 
In order to determine its λmax, absorbance spectrum of cyanidin was measured at the 
wavelength range of 200-800 nm (Figure 3.28). The spectrum showed that the λmax was 585 nm 
in the vible wavelength range. Cyanidin had similar spectra and λmax values when dissolved in 
human serum, PBS, HEPES and DMEM (with and without 10% FBS).  
   
 Figure 3.28: The absorbance spectrum of cyanidin in phosphate buffered saline (PBS) (pH 
7.4), Dulbecco’s Modified Eagle’s Medium (DMEM) (without fetal bovine serum (FBS)) and 
DMEM. Cyanidin was dissolved in each solvent separately (pH 7.4) at a concentration of 100 µM 
followed by the absorbance spectrum measurement at wavelength ranges of 250-800 nm. Cya: 
cyanidin.  
 
 To determine its rate of disappearance, cyanidin (100 µM) was dissolved in different media 
and the change in absorbance was recorded over time at 585 nm (λmax) using a Beckman 
spectrophotometer. Figure 3.29 shows the degradation of cyanidin in PBS (pH 7.4), DMEM with 
and without 10% FBS, human serum and HEPES buffer. The t1/2 values were different in all 
















Cya in PBS Cya in DMEM (without FBS) Cya in DMEM (10% FBS)
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incubated in other media. When PBS was used as a medium, cyanidin had the lowest t1/2 of only 
10.2 + 0.56 min, and the reaction showed biphasic kinetics. Compared to PBS, cyanidin dissolved 
in HEPES had a significantly higher t1/2 (32.6 + 2.38 min). The t1/2 of cyanidin when dissolved in 
DMEM with or without FBS had no significantly different values (21.6 or 18.7 min, respectively).  
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Cya I DMEM no phenol red with FBS
Cya in Plasma
Cya in HEPES pH 7.4
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Figure 3.29: Change in absorbance of cyanidin in different media. The rates of degradation at 
room temperature of cyanidin in PBS pH 7.4, DMEM supplemented with 10% FBS, DMEM with 
no supplementation, human serum, and 25 mM HEPES buffer (pH 7.4) were determined using a 
spectrophotometer. Cyanidin was initially added to the medium at a concentration of 100 µM 
followed by the measurement of the absorbance at 585nm. Representative curves of kinetics at 
room temperature of the change in absorbance at 585 nm are shown of the same reaction over a) 
600 sec and b) 600 min. c) Mean + SD of t1/2 cyanidin in different media calculated by GraphPad 
Prism software following a nonlinear exponential decay model. a Indicates a significant difference 
between human serum and all other groups. b Indicates a significant difference between PBS and 




The absorption spectrum of quercetin (100 µM) when dissolved in PBS was determined 
using a Beckman spectrophotometer. The λmax was found to be 400.0 nm (Figure 3.30). Quercetin 




Figure 3.30: Absorbance spectra for quercetin in different media. Quercetin was added to 
different media at a concentration of 100 µM, and the absorbance spectrum was then measured.  
 
The rate of change in absorbance (at 400 nm) differed when 100 µM quercetin was 
incubated in different media (Figure 3.31). The t1/2 was 63.47 min and 29.61 min when quercetin 
was incubated in DMEM without FBS, and PBS, respectively. However, the t1/2 for quercetin when 
dissolved in DMEM with 10% FBS was not measurable as the plateau was not reached despite the 





















Figure 3.31: Change in absorbance at 380 nm of quercetin in different media. The rate of the 
decrease in the absorbance of 100 µM quercetin in PBS and DMEM (with or without FBS) at room 
temperature was measured in a spectrophotometer. Quer: quercetin.  
Catechin  
 The catechin spectrum and λmax were measured initially (Figure 3.32a) when dissolved in 
PBS and its λmax was determined to be at 280.0 nm. Catechin had similar spectrum and λmax when 
dissolved in DMEM (with and without 10% FBS). It had no apparent changes in absorbance at 280 
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a.                                                                                b.      
  
 
Figure 3.32: Change in absorbance of catechin in different media. a) Spectrum for 300 µM 
catechin when dissolved in PBS pH 7.4. b) The change in absorbance at 280 nm in different media 
at room temperature was measured over time using a plate reader. Cat: catechin.  
Cyanidin-3-glucose (C3G)  
 The degradation of C3G in PBS and DMEM with or without FBS is relatively slow at room 
temperature (Figure 3.33a), with 22%, 25% and 35% of the initial C3G absorbance was lost after 
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   a.                                                                    b.                                        
   
Figure 3.33: Change in absorbance of cyanidin-3-glucose (C3G) in different media a) 
Spectrum for C3G (100 µM) when dissolved in PBS pH 7.4. b) C3G (100 µM) was incubated at 
room temperature in PBS (pH 7.4), and DMEM with or without 10% FBS and absorbance (at 580 
nm) was measured at 20 min intervals in a plate reader. The experiment was terminated after 16 h 
with no apparent plateau in absorbance values.  
 
3.5.2. HPLC analyses of cyanidin degradation and formation of degradation products 
The objective of this experiment was to determine the change in the concentration of 
cyanidin and its degradation products (PCA and PGA) with time. Initially, cyanidin was detected 
immediately after its addition to PBS (pH 7.4) (Figure 3.34a). After 30 min at room temperature, 






















































Figure 3.34: Detection of changes in cyanidin concentration with time using HPLC. 
Cyanidin at a concentration of 100 µM was incubated at room temperature in PBS, pH 7.4, and 
measured by HPLC with UV-vis detection at 525 nm (with reference wavelength 360 nm). a) 
The detection of cyanidin shortly (about 1 min) after addition to PBS 7.4. b) The detection of 
cyanidin 30 min after adding it to PBS 7.4.  
 
An increase in PGA 1 min after addition of cyanidin to PBS was evident (Figure 3.35a and 3.37). 
In addition, Figure 3.35b shows that the peak for PGA in the cyanidin solution after 2 h of 
incubation at room temperature increased significantly. This increase in peak area for PGA reached 
a maximum within 2 h of incubating cyanidin in PBS, as the PGA levels in the cyanidin solution 
















































































































Figure 3.35: Detection of changes in the concentration of PGA with time in a cyanidin 
solution using HPLC. Cyanidin was added to PBS at a concentration of 100 µM followed by 
incubation at room temperature and the measurement of PGA at different intervals using HPLC. 
PGA was detected at 315 nm and a retention time of ~5.28 min: a) soon after adding cyanidin to 
PBS (pH 7.4), b) after 2hr incubation, c) after 4h incubation, and d) after 8h incubation.  
In order to quantify PGA peaks found in cyanidin solutions, a standard curve was 
established for PGA using a pure standard chemical. The standard curve for PGA in PBS (pH 7.4) 
is shown in Figure 3.36. The peaks were detected at a wavelength of 315 nm and a retention time 
of 5.288 min.   
 
Figure 3.36: Phloroglucinaldehye (PGA) standard curve. PGA was dissolved in PBS at 
different concentrations. Each sample was then run through the column following the same HPLC 














































phase started with 10% B from 0 to 2 min.  The percentage of B was at 70% from 2 to 20 min. 
Flow rate was 1 mL min−1 and temperature was 22.0±1°C. The equation which resulted from 
plotting the concentration (µM) vs peak area was used to calculate the concentrations in cyanidin 
solutions.   
 
After calculating the concentration of PGA in a 250 µM cyanidin solution at the different 
incubation periods, a concentration of 140 µM was evident in the first measurement after addition 
of cyanidin to PBS (4-5 min), and a maximum concentration of PGA of 250 µM was reached after 
2 h (Figure 3.37). This maximum concentration was equivalent to the initial concentration of 
cyanidin (250 µM).  
 
Figure 3.37: The change in the concentration of phloroglucinaldehye (PGA) with time in a 
PBS solution of cyanidin. Cyanidin was added at 250 µM to PBS and incubated at room 
temperature, and the PGA levels were determined over time using HPLC with UV-vis detection 
at 315 nm. The concentrations were calculated using a standard curve which plotted the change in 
concentration against the increase in absorbance (Figure 5.35) (in a single measurement at each 




































3.5.3. Mass spectrometry (MS) analyses of cyanidin degradation and degradation product 
formation 
To further understand the degradation/transformation of cyanidin, MS was employed to 
detect the molecular weights of products found in the degradation process. MS results show that a 
product with an m/z value of 154, which corresponds to PCA and PGA, was detected immediately 
after adding cyanidin to neutral 10% methanol in water and remained for at least 6 h (Appendix 
C). Figure 3.38 shows the change in peak intensity at 153 m/z with time. To verify the presence 
of PCA, product ions were generated for the peak at 153 Da (representative of PGA and PCA with 
a molecular weight of 154 Da) using the tandem MS (negative mode) (MS/MS) (Appendix D). 
The peaks generated were then compared to those produced when a PCA standard was subjected 
to similar MS/MS parameters (Appendix E).  
 
Figure 3.38: The change in peak intensity at 153 m/z with time.  Cyanidin was added at 10 µM 
to MS grade water with 10% methanol and incubated at room temperature. The peaks at 153 m/z 
were determined over time using MS. A correlation was then established between the peak 




















The general purpose of this method was to detect any compound that has a mass/charge 
within an m/z range of 303 and 287. Flavylium ion (expected to appear at 285 m/z) was not 
detected immediately after adding cyanidin to the same solvent (10% MS-grade methanol in MS-
grade water) using Q1 (negative mode). However, the peak (at m/z of 285) was detected using 
enhanced full scan. Interestingly, peaks with m/z of 303 corresponding to chalcone and hemiketal 
(302 Da) intermediates were detected at times zero, 2 h and 6 h (Figure 3.39 and Appendix F).  
Unfortunately, no standards were available for chalcone and hemiketal. Therefore, Peakview® 
software was used to predict the product ions of hemiketal and chalcone. MS/MS was used to 
generate product ions for the peak 303. All peaks that appear as product ions were shown plausible 
using the Software (Appendix G). In addition, the structure of the observed product ions were 
rationalized as shown in Figure 3.40. This shows, although not definitive, that the compound 
detected at m/z peak of 303 is most likely either chalcone or hemiketal.  
 
Figure 3.39: The change in peak intensity at 302 m/z with time. Cyanidin was added at 10 µM 
to MS grade water with 10% methanol and incubated at room temperature. The peaks at 302 m/z 
were determined over time using mass spectrometry. A correlation was then established between 
















































































































Figure 3.40: The rationalization of ion products produced by hemiketal and chalcone in 











The human health benefits of anthocyanidins have been well recognized (Khoo et al, 2017). 
In addition to their potent antioxidant activity, we hypothesized that the mitochondriotropic ability 
of anthocyanidins can enhance their bioactivity over other flavonoid subclasses that lack these 
characteristics. Comparative studies between anthocyanidins and other subclasses of flavonoids 
are needed to understand the significance of structural characteristics in exerting a bioactivity. 
Despite their favourable potent bioactivity, anthocyanidins are presumed to degrade rapidly to 
PCA and PGA. Their lack of stability is supported by degradation studies showing the rapid 
disappearance of the flavylium ion. Nevertheless, these studies dismiss the possibility of 
intermediary compounds (such as hemiketal and chalcone) appearance and sustainability.  
Consequently, we set forward a novel series of experiments to show that cyanidin is stable 
for sufficient periods in different media to exert a bioactivity that may surpass that of its 
metabolites (PCA and PGA) and other flavonoids (quercetin, catechin and C3G) in protecting 
differentiated H9c2 cells from mitochondrial ROS-mediated cytotoxicity of doxorubicin. Due to 
its mitochondriotropic characteristics, the hypothesis was that cyanidin would accumulate in the 
mitochondria and exert a better cytoprotective ability compared to flavonoids from different 
subclasses.  
4.1.1. Cytotoxicity of doxorubicin  
Few studies have attempted to investigate in detail the acute effects of doxorubicin on 
mitochondrial ROS generation that may lead to decreases in cardiomyocyte viability and 
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mitochondrial function. Such information is essential for understanding the mechanism in which 
antioxidants protect cardiomyocytes from doxorubicin’s insult. Furthermore, most previous 
studies have used undifferentiated H9c2 cells, which as dividing cells may have a different 
mechanism of doxorubicin cytotoxicity to the in vivo mature differentiated cardiomyocytes 
(Branco et al, 2012; 2015). This difference may lead to inaccuracy in understanding the 
mechanisms of the in vivo cardiotoxicity. Therefore, the time course and mechanisms of 
doxorubicin-induced cytotoxicity in differentiated cardiomyocytes was evaluated in this work. 
Using differentiated H9c2 cells, high concentrations of doxorubicin (5 µM) caused a significant 
reduction in cell survival with short (3 or 6 h) incubation periods when followed by a drug free 
period (24 h). These results indicate doxorubicin’s rapid effect on the cells, which manifests into 
cell death after an extended drug free period. These observations differ from previous reports that 
only showed extensive cell death when doxorubicin was incubated with the cardiomyocytes for 
extended periods (12-48 h) (Branco et al, 2012; Choi et al, 2007).  
Importantly, our in vitro treatment pattern involving short exposure to high doxorubicin 
concentrations mimics the pattern which the heart experiences after intravenous bolus 
administration of doxorubicin in clinical practice (Adriamycin, 2014; Johansen, 1981; Rahman et 
al, 1986). These results imply that doxorubicin can trigger rapid changes in cardiomyocytes which 
by initiating the process of apoptosis manifests into cell death after an extended period, as 
discussed below. These findings are important considering the clinical use of doxorubicin which 
is administered as intravenous bolus injection peripherally once every 7-10 days. With a 
distribution half-life of 12 minutes, the heart will experience very high concentrations of 
doxorubicin for a short period of time before a distribution equilibrium is reached with the rest of 
the tissues and organs of the body (Speth et al, 1988). Furthermore, rapid elimination kinetics 
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(where half-life is only 1-3 h) indicates a relatively short duration of exposure to doxorubicin, 
which is cleared from the body within hours of intravenous administration. Our study with short 
term exposure of differentiated cardiomyoctyes to doxorubicin better reflects the clinical usage of 
doxorubicin as compared with published studies which use longer exposure periods and 
undifferentiated cardiomyocyte cell lines. 
Interestingly, cell density assessments following 3 or 6 h exposure of differentiated H9c2 
cells to 1 µM doxorubicin showed no acute effects on cell survival. This observation possibly rules 
out the pathological process of cellular necrosis as a mechanism of doxorubicin-induced cell death 
in this model. The observation that cell death becomes significant at 12 and 24 h incubation with 
doxorubicin suggested that a more protracted process, such as apoptosis, was the cell death 
mechanism (Fink and Cookson, 2005).  
 Since cell viability (MTT) assessments following 3 or 6 h exposure to doxorubicin showed 
no effects on cell viability, cellular necrosis as a mechanism of doxorubicin-induced cell death is 
likely ruled out. Instead, a more organised process, such as apoptosis, is the potential cell death 
mechanism. Apoptosis is less likely to cause leakage of cellular contents and does not involve 
inflammatory-mediated tissue damage (Fink and Cookson, 2005). Studies involving cytotoxicity 
evaluations with doxorubicin report that apoptosis is the principal mechanism of cell death (Tan 
et al, 2010) supporting the assertion that doxorubicin-mediated toxicity of cardiomyocytes likely 
involves apoptotic mechanisms.  
The delayed cytotoxicity possibly caused by rapid effects, prompted our determination of 
accute effects of doxorubicin on mitochondrial and cellular ROS. At 5 µM, doxorubicin caused an 
elevation in mitochondrial superoxide within 30 min of incubation with the cardiomyocytes 
(Figure 3.5). These results are similar to those of Mukhopadhyay et al (2007), who showed an 
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increase in mitochondrial superoxide within 60 min by 10-50 µM doxorubicin in undifferentiated 
H9c2 cells. Differentiated H9c2 cells are reported to have increased cellular respiration rates as 
compared with undifferentiated H9c2 cells (Patten et al, 2017). Hence, an insult to mitochondria 
(such as that caused by doxorubicin) would have more profound effects in differentiated cells. This 
explains the lower concentration (5 µM) and shorter incubation period (30 min) required in our 
assays to observe an increase in mitochondrial ROS generation. In addition, the increase in ROS 
observed in most in vitro studies after prolonged periods of doxorubicin exposure (eg Bernuzzi et 
al, 2009; Branco et al, 2012; Berthiaume and Wallace, 2007; Cheung et al, 2015; Doroshow and 
Davies, 1986; Hosseinzadah et al, 2011; Kim et al, 2006; Mukhopadhyay et al, 2009; 2007; 
Octavia et al, 2012; Singal and Iliskovic, 1998; Tan et al, 2010; Tsang et al, 2003; Wei et al, 2015) 
likely relates to cellular apoptosis. However, such prolonged exposures with doxorubicin suggests 
apoptosis as a mechanism for ROS increase (Akopova et al, 2012, Chen et al, 2003) rather than a 
direct redox-cycling activity in the heart. 
In contrast, our observations provide evidence for the occurrence of a redox-cycling effect 
as a major cause of doxorubicin-induced mitochondrial superoxide in the differentiated H9c2 cells. 
This rapidly induced effect supports the observation of increased free radical levels caused by 
redox-cycling in isolated mitochondria (Doroshow and Davies, 1986) as a possible mechanism in 
intact cardiomyocytes. Such superoxide production is expected to occur rapidly after the 
interaction of doxorubicin with complex I (Gilliam et al, 2012; Keizer et al 1990; Monsuez et al, 
2010). Since cardiomyocytes rely mainly on aerobic respiration (Stanley, 2004), complex I has a 
crucial role in mitochondrial energy metabolism. Therefore, exposure of cardiomyocytes to 
doxorubicin will likely result in similar redox-cycling and superoxide production. Therefore, our 
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results align with these reports and support the redox-cycling activity in cardiomyocytes as a 
mechanism of cardiotoxicity.    
An increase in mitochondrial superoxide and other ROS may damage mitochondrial 
integrity (decrease the MMP) and energy metabolism (measured by MTT) (Guo et al, 2013; 
Murphy, 2009). However, our results show that the rapid increase in mitochondrial superoxide 
was not correlated with an early (30 or 60 min) increase in intracellular ROS, change in MMP, or 
decrease in energy metabolism (Figures 3.6, 3.7, 3.8), despite the use of high doxorubicin 
concentrations (5 or 20 µM). Instead, extended periods (6-12 h) were required to affect these 
parameters. Upon generation, superoxide molecules can rapidly and spontaneously form other 
derived oxygen reactive species (Powers and Jackson, 2008), react with highly efficient 
endogenous antioxidants that suppress their reactivity, or react with mitochondrial 
macromolecules to cause extensive damage to mitochondrial integrity and function (Forman et al, 
2009; Halliwell, 1994; Halliwell and Gutteridge, 1990; Molina-Heredia et al, 2006; Vranova et al, 
2008). Therefore, the delayed effects on mitochondrial function is most likely due to the extended 
periods required for mitochondrial superoxide and other ROS to reach levels that deplete 
endogenous antioxidants and overwhelm the antioxidant enzymes present, which then allows their 
reaction with mitochondrial macromolecules.  
These overall observations establish that the toxicity of doxorubicin is most likely caused 
by redox-cycling activity which results in a rapid elevation in free radicals. This is manifested in 
cell death and changes to mitochondrial function after extended periods. These new insights into 
the mechanism of doxorubicin-mediated cardiomyocyte toxicity enables investigations into the 




4.1.2. Cytoprotective effects of flavonoids in doxorubicin-induced cardiomyocyte cytotoxicity    
The establishment of the mechanism of doxorubicin’s cytotoxicity (namely elevation in 
mitochondrial free radical levels) suggested that co-administration with a mitochondrial 
antioxidant may mitigate the cytotoxicity observed with its exposure. Therefore, we investigated 
protection by cyanidin compared to other flavonoids. 
Similar to observations from Choi et al (2007), our results showed that cyanidin was able 
to protect H9c2 cells when added after the incubation with doxorubicin. We then coducted 
experiments using differentiated H9c2 cells with the same treatment patterns (Figure 3.9). The 
protection observed when doxorubicin and cyanidin were added consecutively, indicated that cells 
‘affected’ by the insult initially, were subsequently ‘rescued’ by the antioxidant (cyanidin). 
Although encouraging, these results are only evident to the protection of cyanidin against 
apoptosis-mediated cell death. However, since doxorubicin is also suggested to cause a rapid 
redox-cycle mediated ROS elevation in myocytes (Gilliam et al, 2012; Monsuez et al, 2010) an 
approach that inhibits such activity is highly crucial. Our novel treatment pattern of cyanidin 
together with doxorubicin followed by a free drug period (co-treatment and delayed assessment, 
Section 4.3.3.) provided strong evidence of the early protective effects against redox-cycle induced 
ROS. Interestingly, cytoprotection was not observed following co-administration of doxorubicin 
with cyanidin (with single or multiple additions) for 24 h and assessment of cell survival at the end 
of the exposure period (Figure 3.10). The requirement of a drug free period implies that a “limited” 
protection maybe insignificant, hence undetectable initially in the first 24 h, but prevents a decrease 
in cell viability after a further period of time. Thus, cyanidin may have the potential to protect 
cardiomyocytes from the well known cardiotoxicity of doxorubicin when administered together, 
suggesting a possible significant role in clinical practice.  
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 The significance of mitochondria-targeted antioxidants, such as synthetic TPP compounds, 
in some conditions of mitochondrial oxidative stress has been well established (Oyewole and 
Birch-Machin, 2015). However, although the intracellular antioxidant activity of the different 
flavonoids has been previously evaluated using different cellular models (Bornsek et al, 2012; 
Galleano et al, 2010; Kellett et al, 2018), the importance of the mitochondriotropic ability of these 
compounds has not been addressed. To understand the importance of structural characteristics in 
determining the antioxidant and mitochondriotrophic activity of anthocyanins, the cytoprotective 
ability of cyanidin was compared to its glucoside (C3G) and to flavonoids with different charge 
(specifically quercetin and catechin) (Figures 3.11, 3.12, 3.13). Although all flavonoids were 
capable of increasing cell survival in doxorubicin-exposed cardiomyocytes, cyanidin had overall 
higher effectiveness. These enhanced effects were most likely due to the favourable structural 
characteristics of cyanidin which include its more positive charge at physiological pH (compared 
to quercetin and catechin) and suitable lipophilicity (compared to C3G) (Peng, 2012).   
 Our results showed that a short (3 h) co-incubation with cyanidin or C3G suppressed the 
doxorubicin-induced early increase in mitochondrial superoxide (Figure 3.14), which 
mechanistically may help maintain cell viability. The requirement of at least 6 h co-incubation for 
quercetin and catechin implies that they are not as efficient as mitochondrial antioxidants. 
However, the equal ability of quercetin and cyanidin to decrease mitochondrial superoxide 
generation after 30 min exposure to 5 µM doxorubicin shows that they are both effective initially, 
but the protection by cyanidin is retained to a greater extent over time (Figure 3.14). This extended 
protection suggests that the accumulation of cyanidin in the mitochondria for periods longer than 
other flavonoids.  
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In addition, cyanidin and quercetin significantly lowered intracellular ROS generation with 
extended (12 h) doxorubicin exposure, while only cyanidin decreased intracellular ROS at 6 h 
(Figure 3.15). The earlier effect observed with cyanidin suggests a rapid accumulation in the 
mitochondria and ability to preempt later ROS generation. Despite the increase in superoxide and 
ROS generation caused by the extended incubation periods with doxorubicin (12 h), cyanidin and 
quercetin retained their protective effects. The observation is evidence for their initial antioxidant 
activity which lasted for extended periods, and may be related to an ability to prevent apoptosis 
and associated ROS-induced ROS release.  
Effects of doxorubicin and flavonoids on mitochondrial integrity and function were 
evaluated using EM, and measurements of MMP and MTT reduction. EM images 24 h after 
exposure to doxorubicin for 24 h showed that cyanidin was able to prevent changes in 
mitochondrial morphology in this treatment pattern (Figure 3.17). In measurements of MMP after 
12 h doxorubicin exposure however, cyanidin nor other flavonoids tested were able to significantly 
protect mitochondrial integrity. One explanation for the lack of protective activity despite 
significantly lowering ROS at this time point, might be a mechanism independent of ROS that 
affects the MMP when targeted by doxorubicin. For example, doxorubicin can inhibit complex I 
(Gilliam et al, 2013) which affects its ability to move protons to the intermembrane space thus 
reducing MMP. Nevertherless, protection by flavonoids against decreased reduction of MTT, 
which involves complex I, argues against this mechanism. Another explanation might be that 
doxorubicin causes opening of the mitochondrial permeability transition pore (mPTP), which 
allows the free movement of ions and small molecules across the membrane leading to the 
dissipation of the MMP (Gorini et al, 2018). The opening of the mPTP can be reversible at early 
stages or if the stress doesn’t lead to apoptosis (Ly et al, 2003; Crompton, 1999) which could allow 
111 
 
restoration at a later time point. In this way, the protection may become evident at a later time 
point (i.e. after a drug free period). 
Consistent with their effects on mitochondrial superoxide after 6 h exposure to doxorubicin 
(Figure 3.7), cyanidin, quercetin and catechin were able to effectively protect against a decrease 
in mitochondrial energy metabolism, as measured by the MTT assay, at this time point (Figure 
3.16). The MTT assay involves reduction of MTT by complex I of mitochondria, which becomes 
impaired in conditions of oxidative stress and lipid peroxidation (Ahmed Alamoudi et al, 2018) 
through reaction of critical protein thiols with reactive aldehydes and other oxidants (Lin et al, 
2002). Therefore, the protective ability can be a result of protection of thiol groups in complex I 
from lipid peroxides and aldehyde adduct formation. The suitable lipophilicity of these flavonoids 
is highly crucial to protect against lipid peroxidation and inactivation of thiol groups located deep 
in complex I. This may also explain the enhanced MTT protective effects of catechin over C3G 
despite their similar effects on mitochondrial superoxide and ROS levels. The hydrophilicity of 
C3G hinders its spread to lipophilic sites in and around complex I, and hence may limit its 
protective ability and MTT restoration.  
 Cyanidin is thought to degrade rapidly to PCA and PGA in physiologically relevant 
environments (Fang, 2014) and it is commonly believed that the degradation products exert the 
majority of the bioactivity. Yet addition of PCA or PGA to cardiomyocytes had limited 
cytoprotective behaviour as compared with cyanidin (Figure 3.11, 3.12). Perhaps cyanidin itself 
(quinoid form or flavylium ion), or intermediates during the degradation to PCA and PGA, such 
as the hemiketal and/or chalcone were responsible for the cytoprotection observed with cyanidin 
administration. The assumption that the chalcone can exert an antioxidant activity is justified by 
previous reports that showed such behaviour (Bukhari et al, 2012; Lahsasni et al, 2014; Sokmen 
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and Khan, 2016). Supported by previous experiments which detected cyanidin in the heart 30 min 
after its injection to rats (Peng, 2012), our results indicated the survival of the parent compound and/or 
intermediate compound(s) for sufficient periods to exert an activity (Figures 3.29, 3.35, 3.37 and 3.39). 
Our results may also explain the discrepancies in the activities between cyanidin and other 
flavonoids that also degrade to PCA and PGA-like compounds (Rodriguez-Mateos et al, 2014; 
Stevens and Maier, 2016). That is, compounds other than the mutual degradation products PGA 
and PCA (Braune et al, 2001) most likely cause the discrepancies in their bioactivities (Meyer et al, 
1998).  
In addition to their antioxidant activity, different flavonoids were shown to have an important 
effect on different cellular pathways. For example, different flavonoids including anthocyanidins were 
reported to bind with iron metal which may assist in lowing ROS formation (Kaiserova et al, 2007; 
Afanasev et al, 1989). Different flavonoids were also reported to induce endogenous enzymes such 
as glutathione-S-transferase which may further lower ROS levels (Elliott et al, 1992; Filipe et al, 
2002). Another meahcinsm in which anthocyanins can protect the cells is protecting the DNA from 
ROS by forming a DNA triplex complex (Sarma and Sharma, 1999; Mas et al, 2000). 
4.1.3. Accumulation of cyanidin intracellularly 
Our results showed that cyanidin gave better cytoprotection, despite having similar 
antioxidant potency compared to other ortho-dihydroxy flavonoids, such as quercetin and catechin, 
in many antioxidant assays (Meyer et al, 1998, Rice-Evans et al, 1996). Therefore, a difference in 
the intracellular and mitochondrial accumulation of these compounds would explain the enhanced 
cytoprotective activity of cyanidin despite its reduced stability compared to quercetin, catechin 
and C3G. This explanation stems from the reported ability of cyanidin to accumulate in heart cells 
after an IV injection to rats (Peng, 2011). However, no attempt has been made to detect its 
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intracellular levels in cultured cells. Hence, we set forward experiments to determine the difference 
in the intracellular accumulation of the flavonoids using differentiated H9c2 cells.  
UV-vis data showed no success in detecting intracellular cyanidin in H9c2 cells based on 
absorption spectrum (200-800 nm) measurment and the use of a high number of pelleted H9c2 
cells. Measuring of the entire spectrum was an attempt to detect any change in the structure of 
cyanidin caused by metabolism or degradation.  
Furthermore, the failure of the highly sensitive HPLC and MS analytical tools in the 
detection of intracellular cyanidin might be caused by the multiple steps involved in the sample 
preparation despite the use of acidified ACN. In addition, liquid chromatography was used with 
MS (LC-MS) to eliminate the potential effect of electrolytes on detection capabilities. Despite 
these efforts, cyanidin was undetectable intracellularly. Fortunately, the fluorescence 
characteristics of cyanidin enabled its intracellular detection. The wavelengths used matched that 
of cyanidin when dissolved in ACN (0.1% FA) (Appendix G). This further showed that the 
detected fluorescence from intracellular extracts was most likely due to cyanidin. However, due to 
the low sensitivity/specificity compared to fluorescence of control cells, the method would need 
substantial development but could be useful in future studies. Unfortunately, catechin and C3G 
had no detectable fluorescence characteristics which preempted our attempt to detect them 
intracellularly.   
4.1.4. Effect of cyanidin on HepG2 and K562 cells 
To explore whether cyanidin may enhance or mitigate effects of doxorubicin on cancer 
cells, HepG2 liver and K562 lymphocyte cancer cell lines were employed in our studies since 
doxorubicin is often used in liver cancer and leukemia (American Cancer Society, 2016; National 
Cancer Institute, 2018). The potential ability of antioxidants to protect cancer cells from the 
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treatments by lowering ROS is a growing concern. High ROS in cancer cells encourages further 
mutations, which lead to enhancement in cellular proliferation, and cell migration (Liou and Storz, 
2010). Therefore, a reduction in ROS may halt tumor growth and progression (Olsson et al, 2006; 
Tsuda et al, 2013; Wang and Lewers, 2007). Some chemotherapeutics, though, rely on induction 
of ROS to cause cancer death (Teppo et al, 2017). Reduction in ROS levels in conjunction with 
such drugs might mitigate their cytotoxic effects. Despite its antioxidant activity, cyanidin had no 
significant effect on the HepG2 or K562 cell survival or doxorubicin-mediated cytotoxicity and 
alteration in their mitochondrial function (Figures 3.21, 3.22). This provides preliminary evidence 
to a lack of inhibitory effects for this antioxidant when used with doxorubicin.     
In agreement with published reports (Mutlu Altundağ et al, 2018; Zhou et al, 2017), 
quercetin showed potentiating and cytotoxic effects when treated with or without doxorubicin 
against both cancer cell lines (Figures 3.21, 3.22). However, its effects were previously shown to 
be due to its ability to inhibit P-glycoprotein (Limtrakul et al, 2005) and downregulate Bcl-xl 
(Wang et al, 2012) rather than its antioxidant ability. These mechanisms may explain the superior 
potency of quercetin over cyanidin in cancer cells. Consequently, in addition to its cardiomyocyte 
protective ability, quercetin can potentiate doxorubicin’s cytotoxicity. Despite its greater 
cardioprotectant antioxidant activity, cyanidin may not be as ideal as quercetin in cancer therapy.   
4.1.5. Degradation of cyanidin and other flavonoids in cell culture media   
The lack of stability of some flavonoids in different media has been documented in a few 
studies (Hu et al, 2007). However, these studies did not involve comparisons between the different 
flavonoid subclasses. To explore if the bioactivities of the different flavonoids were influenced by 
stability in physiological media, we compared their stability in PBS and cell culture media (with 
or without 10% FBS). Such information is crucial to allow a better understanding of their relative 
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bioactivities, and the chemical species that may be involved. Our results showed a faster 
disappearance of cyanidin than quercetin, catechin and C3G when dissolved in PBS and DMEM 
(Figure 3.29, 3.31, 3.32, 3.33). In agreement with literature (Albuquerque et al, 2017; Kay et al, 
2009), catechin and C3G had relatively enhanced stability in the different media compared to 
cyanidin and quercetin.  
Similar to the literature (Maini et al, 2012), our results showed a degradation of quercetin 
in DMEM (without FBS) with a t½ of 63 min at room temperature (22±1°C), compared to a t½ of 
~ 1 h at 25°C observed by Maini et al (2012). In contrast to the results of Maini et al (2012), who 
found a much slower degradation of quercetin in Dulbecco’s PBS (t½ of ~ 6 h) compared to 
DMEM, we found a lower stability in PBS (t½ of 30 min). Apart from a slight difference in pH 
(7.2, vs 7.4 herein), other explanations for the different results may be less phosphate and the 
possible presence of calcium and magnesium in Dulbecco’s PBS (the paper by Maini et al, 2012, 
didn’t identify the product number or formulation used). Since hydrolysis can be catalyzed by 
phosphate ions (El-Seoud et al, 2002), the presence of these ions might have caused the difference 
in the degradation rate observed between our results.  
The effect of FBS addition to DMEM on the degradation of quercetin has not been 
previously reported. This further emphasises the importance of our finding which showed no effect 
on the degradation of cyanidin, but a substantial improvement on the stability of quercetin in 
DMEM with 10% FBS (t½ > 12 h). A possible explanation for the different effect of FBS on the 
stability of cyanidin and quercetin is the binding ability of each compound to albumin. We 
anticipate a low binding ability of cyanidin to bovine serum albumin compared to a relatively 
strong binding constant between the protein and quercetin (binding constant of 2.8×108 M-1) 
(Wang et al, 2006).  
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In addition, our results highlight the effect of media on the degradation patterns of different 
flavonoids. Hence, careful attention must be made to the difference in the rate of degradation of 
different flavonoids when their bioactivity is studied in cell culture experiments. 
The superior bioactivity of cyanidin despite its rapid disappearance (compared to other 
flavonoids tested in this thesis) suggests different explanations. One explanation may be the 
formation of intermediate(s) (with potent activity) instead of its immediate degradation to the less 
bioactive PCA and PGA. Alternatively, the flavylium ion may enter the cell before its degradation 
in the media. Once in the cells, a stabilizing environment might enhance the stability of cyanidin 
hence allow it to exert a potent activity. One stabilizing factor may be the binding of cyanidin to 
the different proteins or lipids in the cell (particularly in the mitochondria). In addition, since 
anthocyanidins are more stable in an acidic environment, the mitochondrion’s acidic surrounding 
environment can possibly enhance the survival and mitochondrial uptake of cyanidin to allow its 
protective effects against mitochondrial ROS. These factors may offer an explanation to the 
enhanced bioactivity of cyanidin against a mitochondrial stressor such as doxorubicin compared 
to the other flavonoids.  
The rapid degradation of cyanidin to PCA and PGA is hypothesized to occur through the 
formation of hemiketal and chalcone intermediate compounds (Kay et al, 2009). However, no 
attempt was reported to detect these intermediate compounds. Although cyanidin rapidly 
disappears when present in PBS as detected by UV-vis spectrometry, a relatively slow increase in 
the concentration of PCA and PGA was observed with HPLC. These results provide evidence that 
cyanidin does not degrade immediately to PCA and PGA. Instead, relatively stable intermediates 
(hemiketal and chalcone) are formed and survive for a certain time period (~ 6 h). Interestingly, a 
sharp (within 5 min) increase in PCA was detected after the addition of cyanidin to PBS followed 
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by a slower increase with time. This biphasic phenomenon was observed within the first 5 min 
using UV-vis spectrometry. The observed phenomenon is an indication of the rapid degradation 
of cyanidin to an intermediate compound followed by a relatively slow disappearance of the 
intermediates. Furthermore, the observation of such behaviors in PBS but not other media (DMEM 
with or without FBS) is evidence to the variation in the degradation behaviour with different media.   
 The effect of different media on the degradation of cyanidin has been overlooked in the 
literature. The stability of cyanidin in cell culture medium with or without 10% FBS was slightly, 
but not significantly different (t1/2 21.6 min and 18.7 min, respectively). The results surprisingly 
show that 10% FBS had no significant effect on the stability of cyanidin suggesting a minimal 
binding or stabilizing ability, at the experimental conditions employed (with 10% FBS as the 
amount of serum). Differences in the structures of bovine and human albumin (Steinhardt et al, 
1971) may explain the absence of binding ability with FBS compared to human albumin binding 
capacity (cyanidin binding constant of 2.72×105 M-1) (Cahyana and Gordon, 2013). 
Components (mainly salts) present in the media or buffers showed a significant effect on 
the degradation process of cyanidin. For example, its degradation was very fast in PBS (t1/2 of 10.2 
min). Hydrolysis is known to be catalyzed by phosphate ions through general acid-base catalysis 
(El-Seoud et al, 2002). We showed that adding cyanidin to HEPES buffer (which has no phosphate 
ions) improved its stability (t1/2 of 32.6 min). Therefore, the enhancement of cyanidin degradation 
by phosphate (in PBS) suggests hydrolysis as a possible mechanism. In summary, these results 
highlight the importance of understanding the effects of the medium on the stability of cyanidin in 
degradation studies. In addition, our results provide evidence that the degradation of cyanidin to 




4.1.6. Stability of cyanidin in human serum 
  The ultimate relevance of these in vitro studies is the use of cyanidin in dietetic or 
pharmaceutical practice. Importantly, its stability in human serum has not been evaluated 
previously. In addition, knowing that cyanidin degradation depends on the medium, determining 
its stability in human serum is crucial. Our experimental results in human serum suggest that 
cyanidin has adequate stability, with a t1/2 of 43.2 min, for distribution to tissues and clinical 
effectiveness. The increased stability of cyanidin in human serum compared to other media tested 
is most likely due to its binding ability to human serum albumin (Cahyana and Gordon, 2013). 
Moreover, the high concentration of serum proteins, such as albumin (which is ~ 55% of serum 
proteins) in the pure human serum used in our experiments, is 10 fold higher that the concentration 
of serum proteins in DMEM with 10% serum (FBS). The stability of cyanidin in human serum 
supports our initial in vivo observations with cyanidin-injected rats, showing that cyanidin was 
detectable in tissues 30 min after injection (Peng, 2012). These results provide crucial significance 
to the medium used when evaluating the degradation of cyanidin. With a t1/2 of 43.2 min in human 
serum, cyanidin stability is probably suitable for usage in clinical practice. 
4.1.7. Mechanism of cyanidin degradation and formation of products 
 The rapid degradation of cyanidin to PCA and PGA was speculated to occur through the 
formation of intermediate compounds (Kay et al, 2009). Although a rapid (within 5 min) 
disappearance of cyanidin was detected using UV-vis spectrometry when present in PBS (Figure 
3.29), a 2 h period was required for PGA to increase to levels that equaled the initial concentration 
of cyanidin (Figure 3.37). These results agree with published data that showed a rapid decrease in 
cyanidin’s concentration and a slow increase in PCA and PGA (13 h) (Kay et al, 2009). The 
difference in the time required to reach a plateau in PGA levels is most likely caused by a change 
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in the experimental protocol. Instead of injecting the cyanidin sample into the HPLC while 
retaining the neutral pH, Kay’s group mixed it with an acidic mobile phase during injection. This 
may cause a significant change in the equilibrium between the flavylium ion and the intermediate 
compounds leading to a change in the composition of cyanidin’s solution. To avoid this, we used 
similar mobile phases (water and ACN) but kept the pH at 7.4. Despite these differences, both data 
suggest that relatively stable intermediates (hemiketal and chalcone) may have formed and 
survived for a certain period of time. In previous studies, no attempts were reported to detect the 
hemiketal and chalcone intermediate compounds.  
In a novel addition, we also reported a sharp increase in PGA detected soon (within 5 min) 
after the addition of cyanidin to PBS using HPLC. This result suggests an initial rapid degradation 
of cyanidin followed by a slow degradation phase. This biphasic phenomenon was also observed 
in the first withing the first 3 min using UV-vis spectrometry. These observations suggest a rapid 
degradation of cyanidin to PGA (within minutes) passing though the intermediates (phase one). 
Once the concentrations of PGA and PCA reach a specific value, a backward reaction can occur 
between the aldehyde of PGA and the acid of PCA forming a chalcone. This backward reaction 
then slows down the formation of PGA (phase two). The continuation of the spontaneous 
degradation of the flavylium ion will result in the formation of chalcone thus shifting the 
equilibrium towards the formation of PCA and PGA. The process will proceed until the flavylium 
ion is finished. Furthermore, the observation of such behaviors in PBS is anticipated to be caused 
by the phosphate ions found in this medium. A lower concentration or lack of phosphate in other 
media might have slowed the hydrolytic degradation reactions to levels where PCA and PGA are 
slowly formed at a similar pace to the formation of the chalcone. Hence, we hypothesis that only 
one phase of degradation was observed in these media.   
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To observe the presence of the intermediates we followed our HPLC results with MS 
experiments. The results from HPLC were supported by observations from MS that showed the 
immediate disappearance of flavylium ion but the detection of peaks at 302 m/z (representing 
hemiketal and/or chalcone) for at least 6 hours after adding cyanidin to LC/MS grade water (with 
10% methanol). The need for the enhanced full scan employment to detect flavylium ion implies 
its presence at minute concentration or its reduced potential to ionize in the MS instrument. Since 
the flavylium ion was detected when cyanidin was dissolved in acidified 10% methanol in water 
(LC-MS grade) (Appendix F), the ionization of the compound is not presented as an obstacle for 
its detection. Unfortunately, the determination of the concentration of hemiketal and/or chalcone 
was not feasible for the lack of both standard and internal standard compounds. Interestingly, these 
results were obtained when cyanidin was added to water with 10% methanol to increase its 
ionization with MS. Despite its rapid degradation in such solvent (Appendix H), the 
hemiketal/chalcone was detectable for at least 6 hrs.  
In summary, our experimental results show that cyanidin does not degrade immediately to 
PGA and PCA once added to a physiological medium. Instead, depending on the medium used, 
cyanidin (or the intermediary compounds) may survive for extended periods (with a t1/2 of about 
43.2 min). These results agree with previous reports that showed a rapid degradation of cyanidin 
but a slow formation of PGA and PCA (Kay et al, 2009). Without acknowledging the possible 
presence of intermediate compounds (hemiketal and chalcone), an assumption was formed 
indicating that both end products (PCA and PGA) cause the bioactivity. However, our results may 
provide a stronger scientific explanation to the variation in the bioactivities of cyanidin and the 
other flavonoids (Meyer et al, 1998) despite the similar degradation products (Stevens and Maier, 
2016; Rodriguez-Mateos et at, 2014; Braune et al, 2001). We showed that the rapid decrease in 
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cyanidin causes the formation of hemiketal and chalcone which are able to survive for an extended 
period thus explaining the lengthy duration required to increase PCA and PGA to a plateau level.  
4.2. CONCLUSIONS 
 
 Our results provide evidence of the stability of cyanidin for sufficient periods to exert 
bioactivity that exceeds that of its degradation products (PCA and PGA). Our results also show 
doxorubicin’s ability to induce a rapid increase in mitochondrial superoxide generation in 
differentiated H9c2 cardiomyocytes that resulted in delayed cell death. Importantly, doxorubicin-
mediated cytotoxicity and mitochondrial damage was mitigated by the four tested flavonoids, 
cyanidin, quercetin, catechin and C3G. However, results showed that cyanidin had the highest 
bioactivity compared to the other flavonoids. We speculate that cyanidin’s favourable structural 
characteristics, which can allow a higher accumulation of cyanidin intracellularly and in the 
mitochondria, contributed to its greater bioactivity relative to the other tested flavonoids. However, 
our attempts to provide evidence of intracellular accumulation (and in mitochondria) were not 
successful.  Interestingly, cyanidin also had no undesired effects on the cytotoxicity of doxorubicin 
against the cancer cell lines HepG2 and K562. These results present the widely available cyanidin 
as a potentially useful cardioprotector against mitochondrial ROS inducers, including doxorubicin. 
4.3. CHALLENGES AND LIMITATIONS 
 Stability is a major challenge when working with flavonoids in general, particularly with 
anthocyanidins. For this, cyanidin was dissolved initially in DMSO (the most stabilizing solvent) 
and stored at -80oC in small aliquots until needed. Another issue is the effect of pH on its stability. 
Careful attention to the pH of media was always taken when dealing with cyanidin. Another 
limitation to this study is the requirement of high concentrations to observe an effect. Although 
these concentrations may not be relevant nutritionally, they may be achievable pharmaceutically. 
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In addition, apoptosis as a mechanism of cell death induced by doxorubicin in cardiomyocytes was 
not evaluated in this work. Evaluating such mechanism would be significant to propose apoptosis 
as a mechanism of cell death as opposed to necrosis. However, future investigations can involve 
such assay.    
4.4. FUTURE DIRECTIONS  
The presented research highlights the significance of anthocyanidins in protecting the heart 
from mitochondrial oxidative stress inducers such as doxorubicin despite their presumed high 
degradation rate. It also identifies new opportunities and future research directions. 
 Cyanidin was shown to degrade rapidly in different media. However, due to the lack of 
standard compounds, the detection and isolation of the different intermediates was not 
accomplished. A possible approach would be the incorporation of a carbon isotope (13C) atom at 
sites in the structure of cyanidin. MS can then be used to determine the kinetics for the 
disappearance/formation of the different compounds in the degradation pathway. This method will 
further highlight the survival ability of cyanidin parent compound and/or its degradation 
intermediates in different physiological and MS-compatible media. In addition, this method might 
enable the determination of the stabilizing conditions of each compound in the degradation 
pathway to allow its purification. One condition that has a significant role in stabilizing the 
different forms of cyanidin is the acitiy of the vehecle. Therefore, determining the acitiy at which 
certain a structure is stabilized would then allow an attempt to introduce chemical modifications. 
This would positively prevent/lower the degradation of the compound of interest. 
The incorporation of 13C (Zhang et al, 2011) would also facilitate the detection of different 
compounds (flavylium, hemiketal, chalcone) intracellularly using MS in in vitro and in vivo 
studies. Similar to C3G (Ferrars et al, 2014; Czank et al, 2013), a comprehensive understanding 
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of the in vivo pharmacokinetic behaviour of cyanidin and its metabolites would also be achievable 
with the introduction of 13C atom. This method may allow the determination of the bioactive 
components and their accumulation in different tissues and organs of the body. We also propose 
the detection of a labeled cyanidin and its degradation compounds over time in mitochondria in 
vitro. Thus, the formation of the bioactive compounds during the degradation of cyanidin after its 
accumulation in the mitochondria may be an advantageous characteristic. Should cyanidin utilize 
its favourable structural characteristics to accumulate in the mitochondria then degrade to a more 
bioactive compound (eg. chalcone) (Gacche et al, 2008; Lahasasni et al, 2014, Belsare et al, 2010) 
such behaviour would present it as a prodrug. Because synthesizing prodrugs is an accepted 
technique to improve the pharmacokinetics of many medications (Teagarden and Nema, 2007; 
Granero and Amidon, 2006; Ohwada et al, 2002), introducing cyanidin with such behaviour could 
be advantageous. Once established, the introduction of chemical modifications to the structure of 
cyanidin may permit the stabilization of these bioactive compounds.  
Another approach to improve its stability, cyanidin can be incorporated into a nanoparticle 
carrier. Such an approach has been shown effective in improving the stability and potency of 
different compounds when incorporated with heart-targeted nanoparticles (Liu et al, 2014a). 
However, this approach has not been evaluated in the cardioprotective ability of cyanidin. Because 
of their wide availability, nanoparticles with compatible physicochemical characteristics with 
cyanidin must be selected. Initially, stabilisation studies must be conducted to ensure the stability 
of cyanidin-nanoparticle complex. These will also be followed by evaluations to ensure the 
improvement of the stability of cyanidin. In vitro evaluations would then be conducted to 
determine the effect of such incorporation on the protective ability of cyanidin against the 
chemotherapeutic toxicity with cancer cells. Following this, the cytoprotective activity of 
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cyanidin-nanoparticle complex would be evaluated using doxorubicin-mediated cytotoxicity in 
differentiated H9c2 cells.  
 Our initial results which showed cyanidin’s inability to affect doxorubicin toxicity to 
HepG2 and K562 cells were encouraging. However, these results should be followed by large-
scale experiments involving several chemotherapeutic agents (with different mechanisms of 
action) and many antioxidant compounds (from different groups). In addition, cell lines from 10-
15 different cancer types would be utilized for such a screen. Such comprehensive evaluation 
would allow a better understanding of antioxidant use in cancer therapy. Should cancer protection 
behaviour for antioxidants be minimal, the use of these agents would enhance the survival rate by 
protecting different tissues and organs.  
In addition to its ROS-induction in cardiomyocytes, doxorubicin (and possibly other 
chemotherapeutics) are associated with atrial and ventricular fibrillation, QT-prolongation, ST-
elevation and arrhythmias which leads to cardiotoxicity (Guglin et al, 2009; Nousiainen et al, 
1999). Although many mechanisms have been proposed for such changes in the electrocardiogram 
(ECG), ROS is not yet known to have a role in these changes. However, antioxidants such as 
dexrazoxane (Junjing et al, 2010) and proanthocyanidins (Ammar et al, 2013) have shown good 
potency in preventing acute QT prolongation caused by doxorubicin potentially by scavenging 
different ROS (Junjing et al, 2010; Ducroq et al, 2010; Hasinoff et al, 2003). Therefore, as 
antioxidants, flavonoids may prevent doxorubicin-induced ECG changes. Interestingly, in vitro 
assays have been established to predict the effect of compounds on ECG (Hammond and Pollard, 
2005). Inhibition of the alpha subunit of a potassium ion channel in the heart cells is one major 
cause for QT-prolongation and ECG changes (Hammond and Pollard, 2005).  Human embryonic 
kidney 293 (HEK293) cells stably expressing hERG have been used as a model to evaluate the 
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effect of drugs on this channel that underlies QT and ECG changes (Ducroq et al, 2010; Fanoe et 
al, 2009). Therefore, we propose using such simple in vitro system to evaluate the effect of 
doxorubicin and flavonoids on this channel.  
Our in vitro bioactivity and degradation experiments with cyanidin would persuade future 
in vivo work. Doxorubicin with or without cyanidin would be administered intravenously to mice 
followed by recording the ECG to determine the heart protective ability caused by the flavonoid. 
The the protective ability of cyanidin would then be compared to that of other flavonoids (from 
different subgroups). These proposed in vivo experiments would evaluate the relative protective 
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Appendix A: Emission fluorescence scan (Ex: 400 nm) of cyanidin in ACN (0.1% FA). Emission 








































Appendix B: Mean+SD of fluorescence measurement of intracellular protocatechuic acid 
(PCA) and phloroglucinaldehye (PGA).  Fluorescence was not detected in lysates of 
differentiated H9c2 cells treated with PCA and PGA. Excitation and emission wavelength were 





Appendix C: Degradation of cyanidin in %10 methanol water detected by mass spectrometry 
(MS). Cyanidin (10 µM) was added to 10% methanol/water. Applied biosystems MDS SCIEX 
4000 QTRAP MS instrument. Results show the detection of a peak at 153 m/z corresponding to 
154 Da which is the molecular weight for both protocatechuic acid (PCA) and phloroglucinaldehye 
(PGA). Results show that PCA and/or PGA were detected after 0, 1, 2 and 6 h of dissolving 
















Appendix D.a and D.b: Mass spectrometry (MS) detection of protocatechuic acid (PCA) and 
phloroglucinaldehye (PGA) in cyanidin (10 µM) dissolved in 10% methanol in water (v/v). 
Cyanidin was added at 10 µM to %10 methanol in water, and incubated at 25°C followed by the 
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detection of PCA/PGA by MS. The detected peak (153 Da) was then subjected to MS/MS and the 
product ions produced were recorded a) at time zero and b) at 6 h.    
 
 
Appendix E: Mass spectrogram for protocatechuic acid (PCA) standard (10 µM) when 
dissolved in 10% methanol/water (v/v). Results show the daughter ions produced from PCA in 







Appendix F: MS/MS of a solution of cyanidin in 10% methanol in water at different times. 
Stock samples were diluted in a mixture of 90% water and 10% methanol (pH 7.3) to a final 
concentration of 10µM. Immediately after the preparation, samples were directly injected in 
Applied biosystems MDS SCIEX 4000 Q TRAP mass spectrometer .  Results show the detection 
of a peak at 303 m/z corresponding to 304 Da and a small peak at 285 m/z corresponding to 286 
Da at time zero until at least 6 h after adding cyaniding to (pH 7.4). Both chalcone and hemiketal 
have a molecular weight of 304 Da. A very small peak at 285 corresponds to 286 Da which equals 











Appendix G.a and G.b: Image taken from Peakview software showing the matching peaks 
produced by MS/MS (negative mode) for peak 303 with the predicted product ions produced by 















Appendix H: Degradation of cyanidin in LC-grade water with 10% methanol. The 
degradation of cyanidin was measured using UV-vis absorbance at λmax of 600nm. A rapid 
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